

# EVMS COVID-19 MANAGEMENT PROTOCOL

## An overview of the MATH+ and I-MASK+ Protocols

Developed and Updated by Paul Marik, MD, FCP (SA), FRCP (C), FCCP, FCCM.

Professor of Medicine, Chief of Pulmonary and Critical Care Medicine

Eastern Virginia Medical School

December 12<sup>th</sup>, 2020

This is our recommended approach to COVID-19 based on the best (and most recent) literature. This is a highly dynamic topic; therefore, we will be updating the guideline as new information emerges.

EVMS COVID website: [https://www.evms.edu/covid-19/medical\\_information\\_resources/](https://www.evms.edu/covid-19/medical_information_resources/)

Short url: [evms.edu/covidcare](https://www.evms.edu/covidcare)




Intravenous **M**ethylprednisolone  
High Dose Intravenous **A**scorbic Acid (Vitamin C)  
**T**hiamine (Vitamin B1)  
Low Molecular Weight **H**eparin  
**+**  
Statin – Zinc – Vitamin D – Famotidine – Melatonin – Magnesium



Disclaimer: The information in this document is provided as guidance to physicians World-Wide on the prevention and treatment of COVID-19. Our guidance should only be used by medical professionals in formulating their approach to COVID-19. Patients should always consult with their physician before starting any medical treatment.

**Figure 1. The course of COVID-19 and General Approach to treatment**



	Time Course (days)			
	1 - 5	5 - 11	11 - 14	14 - 28
Ground-glass infiltrates		+	++	+++ ++++
Clinical Symptoms		Fever, malaise, cough, headache, diarrhea	SOB – Mild hypoxia ≤4 L/min N/C & aSat < 94%	Progressive hypoxia
Treatment approach		Antiviral Rx	Anti-inflammatory Rx	
Potential therapies	? Interferon-α	ASA	Enoxaparin 60 mg/day	Methylprednisolone 40mg q 12 inc. to 80 mg q 12 if reqd. Enoxaparin 1mg/kg s/c q 12
	IVERMECTIN 12mg	IVERMECTIN 12mg x 2		
	Quercetin + Zinc + Vit C + Vit D	Quercetin + Zinc + Vitamin D + IV Vitamin C		


**THIS IS A STEROID RESPONSIVE DISEASE:  
HOWEVER, TIMING IS CRITICAL**

**Table 1. Pharmacological therapy for COVID by stage of illness: What has worked and what has failed\***


	Pre-exposure/ Post-Exposure/ Incubation	Symptomatic Phase	Pulmonary/ inflammatory phase
Hydroxychloroquine	Unclear benefit	No benefit	?Trend to harm
Remdesivir	n/a	?? Reduced time to recovery No mortality benefit	No benefit
Lopivinar-Ritonavir	n/a	No benefit	No benefit
Interferon $\alpha/\beta$	Inhaled ? Benefit	No benefit	?Trend harm
Tocilizumab	n/a	n/a	No Benefit
Convalescent Serum	n/a	Unlikely	No Benefit
Corticosteroids	n/a	Trend to harm	BENEFIT
Ivermectin	BENEFIT	BENEFIT	BENEFIT

\*based on randomized controlled trials (see supporting information below)


**Figure 2. Timing of the initiation of anti-inflammatory therapy**



**Figure 3. Time course of laboratory tests for COVID-19**



**Figure 4. SARS-Co-V-2 RNA genome**



It should be noted that there is no cure or “Magic-bullet” for the prevention or treatment of COVID-19. However, recently, a number of therapeutic agents have shown promise for both the prevention and treatment of COVID-19 including ivermectin, Vitamin D, quercetin, melatonin and corticosteroids. Furthermore, it is likely that no single drug will be effective in treating this complex disease and that multiple drugs with different mechanisms of action and used in specific phases of the disease will be required.

### **Prophylaxis**

While there is no “Level 1 evidence” that this “cocktail” will prevent/mitigate against COVID-19 we believe there is significant evidence supporting the efficacy of the individual agents included in the prophylactic protocol. This protocol MUST be part of an overall strategy which includes common sense public health measures, i.e. masks, social distancing, and avoidance of large groups of people. Furthermore, it should be noted that there is emerging evidence suggesting that IVERMECTIN may be highly effective in the prevention and treatment of COVID-19. It is important to emphasize that ALL of the medications included in our prophylactic regimen are inexpensive, safe, and widely available.

- Vitamin D3 1000–3000 IU/day. Note RDA (Recommended Daily Allowance) is 800–1000 IU/day. The safe upper-dose daily limit is likely < 4000 IU/day. [1-22] Vitamin D insufficiency has been associated with an increased risk of acquiring COVID-19 and from dying from the disease. Vitamin D supplementation may therefore prove to be an effective and cheap intervention to lessen the impact of this disease, particularly in vulnerable populations, i.e. the elderly, those of color, obese and those living > 45° latitude. [7-22]
- Vitamin C 500 mg BID (twice daily) and Quercetin 250 mg daily. [23-34] It is likely that vitamin C and quercetin have synergistic prophylactic benefit. [35] It should be noted that *in vitro* studies have demonstrated that quercetin and other flavonoids interfere with thyroid hormone synthesis at multiple steps in the synthetic pathway. [36-39] The use of quercetin has rarely been associated with hypothyroidism. The clinical impact of this association may be limited to those individuals with pre-existent thyroid disease or those with sub-clinical thyroidism.[40] In women high consumption of soya was associated with elevated TSH concentrations.[41] The effect on thyroid function may be dose dependent, hence for chronic prophylactic use we suggest that the lowest dose be taken. Quercetin should be used with caution in patients with hypothyroidism and TSH levels should be monitored. It should also be noted quercetin may have important drug-drug interactions; the most important drug-drug interaction is with cyclosporin and tacrolimus. [42] In patients taking these drugs it is best to avoid quercetin; if quercetin is taken cyclosporin and tacrolimus levels must be closely monitored.
- Melatonin (slow release): Begin with 0.3 mg and increase as tolerated to 2 mg at night. [43-50]
- Zinc 30–50 mg/day (elemental zinc). [23,30,32,33,51-55]
- B complex vitamins [56-60]
- **Ivermectin for postexposure prophylaxis** (see ClinTrials.gov NCT04422561). 0.2 mg/kg (12 mg) immediately then repeat day 3.
- **Ivermectin for pre-exposure prophylaxis** (in HCW) and for prophylaxis in high-risk individuals (> 60 years with co-morbidities, morbid obesity, long term care facilities, etc). 0.15–0.2 mg/kg Day 1, Day 3 and then weekly for 10 weeks, followed by biweekly dosing. [5,61-64] (also see ClinTrials.gov NCT04425850). See dosing Table below. NB. Ivermectin has a number of potentially serious drug-drug interactions. Please check for potential drug interaction at [Ivermectin Drug Interactions - Drugs.com](https://www.drugs.com/interactions-check.php?drug=ivermectin). The most important drug interactions occur with cyclosporin, tacrolimus, anti-retroviral drugs, and certain anti-fungal drugs.

- *Optional:* Famotidine 20–40 mg/day [55–61]. Low level evidence suggests that famotidine may reduce disease severity and mortality. However, the findings of some studies are contradictory. While it was postulated that famotidine inhibits the SARS-CoV-2 papain-like protease (PLpro) as well as the main protease (3CLpro) this mechanism has been disputed.[58] Furthermore, a single study suggested that users of PPI's had a significantly increased odds for reporting a positive COVID-19 test when compared with those not taking PPIs, while individuals taking histamine-2 receptor antagonists were not at elevated risk.[62] This data suggest that famotidine may be the drug of choice when acid suppressive therapy is required.
- *Optional/Experimental:* Interferon- $\alpha$  nasal spray for health care workers [54]

**Ivermectin dosing:** 150-200 ug/kg or fixed dose of 12 mg ( $\leq$  80kg) or 18 mg ( $\geq$  80kg).[65] Depending on the manufacturer ivermectin is supplied as 3mg, 6 mg or 12 mg tablets.

50-64.9 kg - 12mg  
 65-79.9 kg - 15mg  
 80-94.9 kg - 18mg  
 95-109.9 kg - 21mg  
 $\geq$  110 kg - 24mg

**Symptomatic patients at home (for the duration of acute symptoms)**

- Vitamin C 500 mg BID and Quercetin 250–500 mg BID
- Zinc 75–100 mg/day (elemental zinc)
- Melatonin 10 mg at night (the optimal dose is unknown) [50]
- Vitamin D3 2000–4000 IU/day. Calcifediol 0.2 mg is an alternative. [66]
- **Highly recommended:** Ivermectin 0.15–0.2 mg/kg orally (repeat on day 3). [1-5,63,67-78] See Table 1, Figure 5 and ClinTrials.gov NCT04523831. See drug-drug interactions above.
- ASA 81–325 mg/day (unless contraindicated). ASA has antiinflammatory, antithrombotic, and antiviral effects.[79,80] Platelet activation may play a major role in propagating the prothrombotic state associated with COVID-19. [81]
- B complex vitamins
- *Optional:* Famotidine 40 mg BID (reduce dose in patients with renal dysfunction) [82-88].
- *Optional:* Vascepa (Ethyl eicosapentaenoic acid) 4g daily or Lovaza (EPA/DHA) 4g daily; alternative DHA/EPA 4g daily. Vascepa and Lovaza tablets must be swallowed and cannot be crushed, dissolved or chewed. Omega-3 fatty acids have anti-inflammatory properties and play an important role in the resolution of inflammation. In addition, omega-3 fatty acids may have antiviral properties. [32,89-92]
- *Optional:* Interferon- $\alpha/\beta$  s/c, nasal spray or inhalation. [93-96] It should be noted that Zinc potentiates the effects of interferon.[97,98]
- In symptomatic patients, monitoring with home pulse oximetry is recommended (due to asymptomatic hypoxia). The limitations of home pulse oximeters should be recognized, and validated devices are preferred.[99] Multiple readings should be taken over the course of the day, and a downward trend should be regarded as ominous.[99] Baseline or ambulatory desaturation  $<$  94% should prompt hospital admission. [100] The following guidance is suggested: [99]

- Use the index or middle finger; avoid the toes or ear lobe
- Only accept values associated with a strong pulse signal
- Observe readings for 30–60 seconds to identify the most common value
- Remove nail polish from the finger on which measurements are made
- Warm cold extremities prior to measurement
- *Not recommended:* Hydroxychloroquine (HCQ). The use of HCQ is extremely controversial.[101] The best scientific evidence to date suggests that HCQ has no proven benefit for post exposure prophylaxis, for the early symptomatic phase and in hospitalized patients. [102-120] Considering the unique pharmacokinetics of HCQ, it is unlikely that HCQ would be of benefit in patients with COVID-19 infection (it takes 5–10 days to achieve adequate plasma and lung concentrations).[112,121-123] Finally, it should be recognized that those studies which are widely promoted to support the use of HCQ are severely methodologically flawed.[124-127]
- *Not recommended:* Systemic or inhaled corticosteroids (budesonide). In the early symptomatic (viral replicative phase), corticosteroids may increase viral replication and disease severity.[128] An OpenSAFELY analysis in patients with COVID-19 demonstrated a higher risk of death in COPD and asthmatic patients using high dose ICS. [129] The role of ICS in the pulmonary phase is unclear as patients require systemic corticosteroids to dampen the cytokine storm, with ICS having little systemic effects.

## I-MASK+

### PROPHYLAXIS & EARLY OUTPATIENT TREATMENT PROTOCOL FOR COVID-19

#### PROPHYLAXIS PROTOCOL

<b>Ivermectin</b>	<i>Prophylaxis for high risk individuals</i> 0.2 mg/kg* – one dose on day 1 and day 3, then take one dose weekly for 10 weeks, followed by one dose every 2 weeks**  <i>Post COVID-19 exposure prophylaxis***</i> 0.2 mg/kg* – one dose on day 1 and day 3
<b>Vitamin D3</b>	1,000–3,000 IU/day
<b>Vitamin C</b>	1,000mg twice a day
<b>Quercetin</b>	250mg/day
<b>Zinc</b>	50mg/day
<b>Melatonin</b>	6 mg before bedtime (causes drowsiness)

#### EARLY OUTPATIENT PROTOCOL\*\*\*\*

<b>Ivermectin</b>	0.2 mg/kg* – one dose on day 1 and day 3
<b>Vitamin D3</b>	4,000 IU/day
<b>Vitamin C</b>	2,000 mg 2-3 times daily
<b>Quercetin</b>	250mg twice a day
<b>Zinc</b>	100mg/day
<b>Melatonin</b>	10 mg before bedtime (causes drowsiness)
<b>Aspirin</b>	325mg/day (unless contraindicated)

#### Behavioral Prophylaxis



#### WEAR MASKS

Must wear cloth, surgical, or N95 mask (without valve) in all indoor spaces with non-household persons.

Must wear a N95 mask (without valve) during prolonged exposure to non-household persons in any confined, poorly ventilated area.



#### KEEP DISTANCE

Until the end of the Covid-19 crisis, we recommend keeping a minimum distance of approx. 2m / 6 feet in public from people who are not from your own household.



**Mildly Symptomatic patients (on floor/ward in hospital):**

- Vitamin C 500–1000 mg q 6 hourly and Quercetin 250–500 mg BID (if available)
- Zinc 75–100 mg/day
- Melatonin 10 mg at night (the optimal dose is unknown) [50]
- Vitamin D3 20,000–60,000 IU single oral dose. Calcifediol 0.2–0.5 mg is an alternative. [66] This should be followed by 20,000 IU D3 (or 0.2 mg calcifediol) weekly until discharged from hospital. Calcifediol is more efficiently absorbed, achieves 25-OH vitamin D levels quicker and is three times more potent than vitamin D3. [130,131] However, it is important to note that the optimal dose of vitamin D in the acute setting is unknown.[132,133] Very high doses may paradoxically block the vitamin D receptor.
- **Highly recommended:** Ivermectin 0.15–0.2 mg/kg orally (12 mg) and repeat on day 3 [1-5,63,67-77]. It should be noted that ivermectin has potent anti-inflammatory properties apart from its antiviral properties.[134-136] See Table 1 and Figure 5. See drug-drug interaction above.
- Enoxaparin 60 mg/day [75,137-150] Consider increasing the dose to 1mg/kg q 12 hourly in those with a high D-Dimer or an increasing D-Dimer (see Xa monitoring below).
- ASA 325 mg (if not contraindicated). Moderate-severe COVID infection results in profound platelet activation contributing to the pro-thrombotic state and increasing the inflammatory response.[151-153]
- Methylprednisolone 40 mg q 12 hourly; increase to 80 mg and then 125 mg q 12 hourly in patients with progressive symptoms and increasing CRP. There is now **overwhelming and irrefutable evidence** that corticosteroids reduce the risk of death in patients with the pulmonary phase of COVID-19 i.e. those requiring supplemental oxygen or higher levels of support. [154-166] The role of inhaled corticosteroids (budesonide) is unclear and appears to be rather limited.
- B complex vitamins
- *Optional:* Famotidine 40 mg BID (20–40 mg/day in renal impairment). [82-88]
- *Optional:* Vascepa (Ethyl eicosapentaenoic acid) 4g daily or Lovaza (EPA/DHA) 4g daily; alternative DHA/EPA 4g daily.
- **Optional (not recommended):** Remdesivir 200 mg IV loading dose D1, followed by 100mg day IV for 9 days. [167,168] This agent has been reported to reduce time to recovery (based on an ordinal scale) in patients requiring low levels of supplemental oxygen. [168,169] The recently published SOLIDARITY trial demonstrated no mortality benefit of this agent in the entire treatment cohort or any subgroup.[170] Considering the high cost of this agent and the lack of benefit on patient centered outcomes the role of this drug seems very limited.
- N/C 2L/min if required (max 4 L/min; consider early t/f to ICU for escalation of care).
- Avoid Nebulization and Respiratory treatments. Use “Spinhaler” or MDI and spacer if required.
- T/f EARLY to the ICU for increasing respiratory signs/symptoms, increasing oxygen requirements and arterial desaturation.

**Progressive Respiratory symptoms (hypoxia- requiring N/C  $\geq$  4 L min: admit to ICU):**

**Essential Treatment (dampening the STORM); MATH + [171]**

1. **Methylprednisolone** 80 mg loading dose then 40 mg q 12 hourly for at least 7 days and until transferred out of ICU. In patients with an increasing CRP or worsening clinical status increase the dose to 80 mg q 12 hourly (then 125mg q 12 hourly), then titrate down as appropriate. [154-166] Pulse methylprednisolone 250–500 mg mg/day may be required.[164] As depicted in Table 1, methylprednisolone is the corticosteroid of choice.
2. **Ascorbic acid (Vitamin C)** 3g IV q 6 hourly for at least 7 days and/or until transferred out of ICU.[27,172-183]. Note caution with POC glucose testing (see below). Oral absorption is limited by saturable transport and it is difficult to achieve adequate levels with PO administration. Should IV Vitamin C is not available, attempts should be made to administer PO vitamin C at a dose of 1g every 4–6 hours. *Mega-dose vitamin C* should be considered in severely ill patients and as salvage therapy: 25g vitamin C in 200-500 cc saline over 6 hours daily for 4 days, then 3g IV q 6 hourly for total of 7-10 days of treatment. [184] (also see <https://www.youtube.com/watch?v=Au-mp6RZjCQ> )
3. **Full anticoagulation:** Unless contraindicated we suggest FULL anticoagulation (on admission to the ICU) with enoxaparin, i.e., 1 mg kg s/c q 12 hourly (dose adjust with Cr Cl < 30mls/min). There is now good evidence that **high intensity anticoagulation reduces mortality** of hospitalized patients with COVID-19. [137,139,140,142-150,185] Heparin is suggested with CrCl < 15 ml/min. Due to augmented renal clearance patients may have reduced anti-Xa activity despite standard dosages of LMWH.[186] We therefore recommend monitoring anti-Xa activity in underweight and obese patients, those with chronic renal failure and in those patients with an increasing D-dimer, aiming for an anti-Xa activity of 0.6–1.1 IU.ml.

Note: A falling SaO<sub>2</sub> and the requirement for supplemental oxygen should be a trigger to start anti-inflammatory treatment (see Figure 2).

Note: Early termination of ascorbic acid and corticosteroids will likely result in a rebound effect with clinical deterioration (see Figure 6).

**Additional Treatment Components (the Full Monty)**

4. **Highly recommended:** Ivermectin 0.15–0.2 mg/kg orally and repeat on day 2 (see doing above). [1-3,67,70-78,134-136,187-194] Note that ivermectin has potent antiviral and anti-inflammatory effects. See Table 1 and Figure 5.
5. Melatonin 10 mg at night (the optimal dose is unknown).
6. Calcifediol 0.2–0.5 mg. [66] This should be followed by 0.2 mg calcifediol weekly until discharged from hospital. Vitamin D3 takes many days to be converted to 25OH vitamin D; [195] this may explain the lack of benefit of D3 in patients hospitalized with severe COVID-19. [196]
7. Thiamine 200 mg IV q 12 hourly [197-202] Thiamine may play a role in dampening the cytokine storm. [198]
8. ASA 325 mg. COVID infection results in profound platelet activation contributing to the severe pro-thrombotic state and increasing the inflammatory response.[151-153] As the risk of significant bleeding is increased in patients receiving both ASA and heparin, ASA should therefore not be used in patients at high risk of bleeding. In addition (as noted below) patients should receive famotidine concurrently.
9. B complex vitamins
10. Magnesium: 2 g stat IV. Keep Mg between 2.0 and 2.4 mmol/l. [59] Prevent hypomagnesemia (which increases the cytokine storm and prolongs Qtc). [203-205]

11. *Optional:* Doxycycline 100mg daily for 5 days. Doxycycline is a broad-spectrum antibiotic which has synergistic anti-viral and anti-inflammatory effects when combined with Ivermectin. [6,68,73,206]
12. *Optional (Consider in severe cases).* Anti-serotonin agents. Platelet activation results in the release of serotonin, which may contribute to the “cytokine storm”. [207]Therefore, the serotonin receptor blocker cyproheptadine 4–8 mg PO q 6 hours should be considered.
13. *Optional.* Atorvastatin 80 mg/day. Statins have pleotropic anti-inflammatory, immunomodulatory, antibacterial, and antiviral effects. In addition, statins decrease expression of PAI-1. Simvastatin has been demonstrated to reduce mortality in the hyper-inflammatory ARDS phenotype. [208] Preliminary data suggests atorvastatin may improve outcome in patients with COVID-19.[209-213] Due to numerous drug-drug interactions simvastatin should be avoided.
14. *Optional:* Famotidine 40 mg BID (20–40 mg/day in renal impairment). [82-88].
15. *Optional:* Vascepa, Lovaza or DHA/EPA 4g day (see above).
16. *Not recommended:* The role of azithromycin in the treatment of COVID-19 is controversial. The best information to date suggests that azithromycin is of little benefit.[214,215]
17. *Not recommended:* Remdesivir. Has not benefit at this stage of the disease.
18. *Not recommended.* Convalescent serum [216,217] or monoclonal antibodies. (Eli Lilly recently announced that they are suspending their ACTIV-33 clinical trial as their monoclonal antibody failed to demonstrate a clinical benefit in hospitalized patients).
19. *Not recommended.* Tocilizumab. Four RCTS have now failed to demonstrate a clinical benefit from tocilizumab. [218-221]
20. Broad-spectrum antibiotics if superadded bacterial pneumonia is suspected based on procalcitonin levels and resp. culture (no bronchoscopy). Due to the paradox of hyper-inflammation and immune suppression (a major decrease of HLA-DR on CD14 monocytes and T cell dysfunction) secondary bacterial and fungal infection is not uncommon. [222]
21. Maintain *EUVOLEMIA* (this is not non-cardiogenic pulmonary edema). Due to the prolonged “symptomatic phase” with flu-like symptoms (6–8 days) patients may be volume depleted. Cautious rehydration with 500 ml boluses of Lactate Ringers may be warranted, ideally guided by non-invasive hemodynamic monitoring. Diuretics should be avoided unless the patient has obvious intravascular volume overload. Avoid hypovolemia.
22. Early norepinephrine for hypotension. It should however be appreciated that despite the cytokine storm, vasodilatory shock is distinctly uncommon in uncomplicated COVID-19 (when not complicated by bacterial sepsis). This appears to be due to the fact that TNF- $\alpha$  which is “necessary” for vasodilatory shock is only minimally elevated.
23. Escalation of respiratory support (steps); **Try to avoid intubation if at all possible**, (see Figure7)
  - Accept “permissive hypoxemia” (keep O<sub>2</sub> Saturation > 84%); follow venous lactate and Central Venous O<sub>2</sub> saturations (ScvO<sub>2</sub>) in patents with low arterial O<sub>2</sub> saturations
  - N/C 1–6 L/min
  - High Flow Nasal canula (HFNC) up to 60–80 L/min
  - Trial of inhaled Flolan (epoprostenol)
  - Attempt proning (cooperative repositioning-proning) [223,224]
  - Intubation ... by Expert intubator; Rapid sequence. No Bagging; Full PPE. Crash/emergency intubations should be avoided.
  - Volume protective ventilation; Lowest driving pressure and lowest PEEP as possible. Keep driving pressures < 15 cm H<sub>2</sub>O.
  - Moderate sedation to prevent self-extubation
  - Trial of inhaled Flolan (epoprostenol)
  - Prone positioning.


There is widespread concern that using HFNC could increase the risk of viral transmission. There is however, no evidence to support this fear. HFNC is a better option for the patient and the health care system than intubation and mechanical ventilation. CPAP/BiPAP may be used in select patients, notably those with COPD exacerbation or heart failure.

A sub-group of patients with COVID-19 deteriorates very rapidly. Intubation and mechanical ventilation may be required in these patients.

**Table 2: Comparison of Methylprednisolone, Dexamethasone and Hydrocortisone- Number Need to Treat (NNT)**

PUBLISHED RCT's/COHORT STUDIES OF CORTICOSTEROID THERAPY IN COVID-19		ABSOLUTE DIFFERENCE IN MORTALITY RATE (Rx Group vs. Control Group)	ESTIMATED NUMBER NEEDED TO TREAT TO SAVE ONE LIFE
METHYLPREDNISONE – HOSPITAL PATIENTS (Edalatifard et al, Iran)		5.9% vs. 42.9%	2.7
METHYLPREDNISONE – ICU PATIENTS (Salton et al, Italy)		7.2% vs. 23.3%	6.2
METHYLPREDNISONE – HOSPITAL PATIENTS, (Fadel et al, USA)		13.6% vs. 26.3%	7.8
METHYLPREDNISONE- ARDS PATIENTS (Wu C et al- China)		46.0% vs. 61.8%	6.3
METHYLPREDNISONE - Pts on oxygen – (Fernandez-Cruz, Spain)		13.9% vs. 23.9%	10.0
<b>CoDEX –DEXAMETHASONE - MECHANICAL VENTILATION</b>		<b>56.3% vs 61.5%</b>	<b>19.2</b>
<b>RECOVERY TRIAL (DEXAMATHASONE)</b>	<b>PTS ON OXYGEN</b>	<b>23.3% vs. 26.2%</b>	<b>28.6</b>
	<b>PTS ON MV</b>	<b>29.3% vs. 41.4%</b>	<b>8.4</b>
HYDROCORTISONE -CAPE-COVID – ICU Patients (Dequin et al France)		14.7% vs 27.4%	7.9
HYDROCORTISONE –REMAP-CAP – ICU patients		28%% vs 33%	20.0

**Figure 5. Metaanalysis of Ivermectin clinical studies (in hospital mortality)**



**Meta Analysis**

**24. Salvage Treatments**

- High dose bolus corticosteroids; 250–500 mg/day methylprednisolone [162,164] Plasma exchange [225-231]. Should be considered in patients with progressive oxygenation failure despite corticosteroid therapy as well as in patients with severe MAS. Patients may require up to 5 exchanges. FFP is required for the exchange; giving back “good humors” appears to be more important than taking out “bad humors”.
- Mega-dose vitamin C should be considered in severely ill patients and as salvage therapy: 25g vitamin C in 200-500 cc saline over 6 hours daily for 4 days, then 3g IV q 6 hourly for total of 7-10 days of treatment. [181] (also see <https://www.youtube.com/watch?v=Au-mp6RZjCQ>)
- In patients with a large dead-space ventilation i.e. high PaCO<sub>2</sub> despite adequate minute ventilation consider “Half-dose rTPA” to improve pulmonary microvascular blood flow; 25mg of tPA over 2 hours followed by a 25mg tPA infusion administered over the subsequent 22 hours, with a dose not to exceed 0.9 mg/kg followed by full anticoagulation.[232,233]
- ECMO [234,235]. Unlike “typical ARDS” COVID-19 patients do not progress into a resolution phase. Rather, patients with COVID-19 may progress to a severe fibro-proliferative phase and ventilator dependency. ECMO in these patients would likely serve little purpose. ECMO however may improve survival in patients with severe single organ failure (lung) if initiated within 7 days of intubation. [236]
- Combination inhaled nitric oxide (or epoprostenol) and intravenous almitrine. The combination of inhaled nitric oxide, a selective pulmonary vasodilator, and almitrine, a specific pulmonary vasoconstrictor, may improve the severe V/Q mismatch in patients with severe COVID-19 “pneumonia”. [237-240]

**Figure 6. Premature discontinuation of corticosteroids and IV vitamin C (after 4 day) and the effect of reinitiation of this combination on the CRP profile.**



**Salvage treatments of unproven/no benefit.**

- Convalescent serum/monoclonal antibodies: the role and timing of convalescent serum and monoclonal antibodies are uncertain. [241-244] Two RCT's failed to demonstrate any clinical benefit with convalescent serum. [216,217] In addition, Eli Lilly recently announced that they are suspending their ACTIV-33 clinical trial as their monoclonal antibody failed to demonstrate a clinical benefit in hospitalized patients. It is noteworthy that the only RCT demonstrating efficacy of convalescent plasma for an infectious disease was conducted more than 40 years ago, for treating Argentine hemorrhagic fever. [211] Furthermore, giving antibodies directed against SARS-CoV-2 appears pointless when the virus is already DEAD (pulmonary phase). In addition, IgG is a large protein which penetrates tissues poorly, and is unlikely to achieve submucosal concentrations required for mucosal immunity.[245] And lastly, COVID-19 pulmonary disease is immune mediated, and it would therefore appear paradoxical to enhance the antibody response with convalescent serum. [246]
- Janus Kinase inhibitors downregulate cytokine expression and may have a role in this disease. [247-249] The role of the combination of Baricitinib and Remdesivir is unclear.[250]
- In patients with progressive fibrosis the combination of anti-fibrotic therapy with corticosteroids should be considered. [251-254] It should however be recognized that unlike all the medications in the MATH+ protocol, pirfenidone and nintedanib have complex side-effects and drug interactions and should be prescribed by pulmonary physicians who have experience with these drugs.
- CVVH/D with cytokine absorbing/filtering filters [255,256] This treatment strategy appears to have a very limited role.

## 25. Treatment of Macrophage Activation Syndrome (MAS)

- A sub-group of patients will develop MAS, particularly those patients with severe COVID-19 disease.[257] While the pathophysiology of MAS in the setting of COVID-19 is unclear this appears to be driven by SARS-CoV-2 induced inflammasome activation and increased IL-18 production as well as increased GM-CSF and INF $\gamma$  production. [258-261] The role of IL-1 and IL-6 in the pathogenesis of MAS is unclear.
- A ferritin > 4400 ng/ml is considered diagnostic of MAS. Other diagnostic features include increasing AST/ALT and CRP and progressive multi-system organ failure.[262]
- “*High dose corticosteroids.*” Methylprednisolone 120 mg q 6–8 hourly for at least 3 days, then wean according to Ferritin, CRP, AST/ALT (see Figure 8). Ferritin should decrease by at least 15% before weaning corticosteroids.
- Consider plasma exchange.
- The role of inhibition of IL-1 (Anakinra) and IFN $\gamma$  (emapalumab) is unclear (NCT04324021).


## 26. Monitoring

- On admission: Procalcitonin (PCT), CRP, BNP, Troponins, Ferritin, Neutrophil-Lymphocyte ratio, D-dimer and Mg. CRP and D-dimer are important prognostic markers. A PCT is essential to rule out coexisting bacterial pneumonia.
- Daily: *CRP, Ferritin, D-Dimer and PCT.* CRP and Ferritin track disease severity closely (although ferritin tends to lag behind CRP). Early high CRP levels are closely associated with the degree of pulmonary involvement and the CT score. [263]
- In patients receiving IV vitamin C, the Accu-Chek™ POC glucose monitor will result in spuriously high blood glucose values. Therefore, a laboratory glucose is recommended to confirm the blood glucose levels. [264,265]
- No routine CT scans, follow CXR and chest ultrasound.
- ECHO as clinically indicated; Pts may develop a severe “septic” cardiomyopathy.




Figure 7.

**General schema for respiratory support in patients with COVID-19**  
**Try to avoid intubation if possible**





**Figure 8. SARS-CoV-2 induced Macrophage Activation Syndrome (MAS) treated with Vitamin C 3g IV q 6 and increased methylprednisolone (125 mg q 8 hourly)**



## 27. Post ICU management

- a. Enoxaparin 40–60 mg s/c daily
- b. Methylprednisolone 40 mg day, then wean slowly (follow CRP)
- c. Vitamin C 500 mg PO BID
- d. Melatonin 3–6 mg at night
- e. Vascepa, Lovaza or DHA/EPA 4g day (important for resolution of inflammation)

## 28. Post Hospital Discharge management


- a. Patients have an increased risk of thromboembolic events post-discharge. [266] Extended thromboprophylaxis (? with a DOAC) should be considered in high risk patients. Risk factors include:[267]
  - i. Increased D dimer (> 2 times ULN)
  - ii. Increased CRP (> 2 times ULN) [268]
  - iii. Age > 60
  - iv. Prolonged immobilization
- b. The *post-COVID-19 syndrome (long haul syndrome)*, is characterized by prolonged malaise, headaches, generalized fatigue, painful joints, dyspnea, chest pain and cognitive dysfunction.[269-274] Up to 50% of patients experience prolonged illness after Covid-19. The post-COVID-19 syndrome may persistent for months after the acute infection and almost half of patients report reduced quality of life. The neurological symptoms may be related micro- and/or macrovascular thrombotic disease which appears to be common in severe COVID-19 disease.[257] Brain MRIs' 3 months post-infection demonstrated micro-structural changes in 55% of patients. [275] Similar to patients who have recovered from septic shock, [276] a prolonged (many months) immune disturbance with elevated pro- and anti-inflammatory cytokines may contribute to the post-COVID-19 syndrome. Consequently, A CRP should be measured prior to discharge and a tapering course of corticosteroids should be considered in those with an elevated CRP. It should be noted that much like omega-3 fatty acids corticosteroids have been demonstrated to increase expression of pro-resolving lipids including Protectin D1 and Resolvin D4.[277] Other interventions that should be considered include:
  - i. Vascepa, Lovaza or DHA/EPA 4g day; important for resolution of inflammation by inducing resolvin production. [91,92]
  - ii. Atorvastatin 40 mg daily (increase resolvin synthesis) [278]
  - iii. Continue melatonin for its antioxidant properties and stabilization of the circadian rhythms.
  - iv. Multivitamin with adequate vitamin D.
  - v. Recently Ivermectin has been reported to have a role in the treatment of post-Covid-19 syndrome. [279] The anti-inflammatory properties of ivermectin may mediate this benefit.
- c. *Post-COVID-19 pulmonary fibrosis*. An unknown number of patients who have recovered from COVID-19 organizing pneumonia will develop pulmonary fibrosis with associated limitation of activity. These patients should be referred to a pulmonologist with expertise in pulmonary fibrosis. Anti-fibrotic therapy may have a role in these patients, [251-254] however additional data is required before this therapy can be more generally recommended.

## 29. Maintaining mental health and the avoiding the misinformation pandemic

*'Misinformation on the Coronavirus might be the most contagious thing about it'*

Dr. Tedros, WHO Director General

- The Panic and misinformation spread by Social Media travels faster than the pandemic itself. What you can do?
  - Avoid social media as much as possible; excess social media exposure increases the likelihood of anxiety and depression[280]
  - Read the news/information from reliable sources (if you can find one)
  - Have a designated time for checking information
  - People share false claims about COVID-19 partly because they simply fail to think sufficiently about whether or not the content is accurate when deciding what to share. [281]
  - Stay connected to positive people! Remotely!
  - Have a plan for staying in touch with family and friends
  - Identify positive influencers...limit contact with other "worriers"
  - Isolation can cause rumination/anxious thinking to escalate
  - Maintain a sense of *hope, humanity and kindness toward others*
  - Seek professional help if anxiety is overwhelming
- Recognize the things you can control
  - WEAR A MASK when in contact with others
  - Establish social distancing; stand/sit about 6 feet away from others
  - Limit attendance at large gatherings
  - Eliminate your contact with those who are ill
  - DON'T go to work or school if you are sick
  - Practice self-care
    - Good sleep, balanced diet, exercise
    - Mindfulness/Meditation/Relaxation activities



## Key Concepts of the FLCCC Alliance Treatment Protocol

This is a very complex disease; many of the mysteries are still unravelling. However, a number of concepts are key to the management of this “treatable disease; they include.

1. Patients transition through a number of different phases (clinical stages). The treatment of each phase is distinct ... this is critically important (see Figures 1 & 2).
2. Antiviral therapy is likely to be effective only during the viral replicative phase whereas anti-inflammatory therapy is expected to be effective during the pulmonary phase and possibly the post-COVID-19 phase. While Remdesivir is a non-specific antiviral agent that targets RNA viruses, it is likely that agents specifically designed to target SARS-CoV-2 will be developed.
3. The SARS-CoV-2 PCR remains positive for at least 2 weeks following detection of whole virus (by culture, See figure 3). Patients who progress to the pulmonary phase are usually PCR positive despite cessation of viral replication (and are therefore less likely to be infectious).
4. Due to the imperfect sensitivity of the PCR test as many as 20% of patients who progress to the pulmonary phase will be PCR negative (even on repeat testing). At symptom onset PCR will be positive in approximately 60% of patients; maximal positivity rate is on day 8 (post infection) when 80% of patients will be positive (see Figure3). [282]
5. Symptomatic patients are likely to be infectious during a narrow window starting 2–3 days before the onset of symptoms and to up to 6 days after the onset of symptoms (see Figure 3).[283]
6. It is important to recognize that COVID-19 patients present with a variety of phenotypes, likely dependent on inoculum size and viral load, genetic heterogeneity mutations and polymorphisms, biotypes, blood type, sex and androgen status, age, race, BMI (obesity), immunological and nutritional status, and co-morbidities.[157,284-294] The phenotype at presentation determines the prognosis and impacts the optimal approach to treatment.
7. The pulmonary phase is characterized by immune dysregulation, [247,249,257,260,261,287,295-304] a pulmonary microvascular injury (vasculopathy),[257,304-307] with activation of clotting and a pro-coagulant state together with the characteristics of an organizing pneumonia. [308,309]
8. **Endothelial damage and an imbalance of both innate and adaptive immune responses, with aberrant macrophage activation, plays a central role in the pathogenesis of the severe COVID-19 Disease. [257]**
9. As patients, progress down the pulmonary cascade the disease becomes more difficult to reverse. The implications of this are twofold.
  - a. **Early treatment (of the pulmonary phase) is ESSENTIAL to a good outcome.**
  - b. Treatment in the late pulmonary phase may require escalation of the dose of corticosteroids as well as the use of salvage methods (i.e. plasma exchange). However, patients who present in the late pulmonary phase may have progressed to the irreversible pulmonary fibroproliferative phase (see Figure 9).
10. The pulmonary phase of COVID-19 is a treatable disease; it is inappropriate to limit therapy to “supportive care” alone. Furthermore, it is unlikely that there will be a single “silver bullet” to treat severe COVID-19 disease. Rather, patients will require treatment with multiple drugs/interventions that have synergistic and overlapping biological effects. Repurposed FDA approved drugs that are safe, inexpensive, and “readily” available are likely to have a major therapeutic effect on this disease. The impact of COVID-19 on middle- and low-income countries is enormous; these countries are not able to afford expensive propriety “designer” molecules.
11. The radiographic and pathological finding of COVID-19 lung disease are characteristic of a secondary organizing pneumonia (and not ARDS). [308,310,311]

12. **THIS is NOT ARDS** (at least initially). The initial pulmonary phase neither looks like, smells like nor is ARDS.[312-314] The ground glass infiltrates are peripheral and patchy, [310] and do not resemble the dependent air space consolidation (sponge/baby lung) seen with “typical ARDS”. [315] Extravascular lung water index (EVLWI) is normal or only slightly increased; this by definition excludes non-cardiogenic pulmonary edema (ARDS). Lung compliance is normal (this excludes ARDS). Patients are PEEP unresponsive. Treating patients as if they ARDS is a very dangerous approach. The hypoxia is due to severe ventilation/perfusion mismatch likely due to the microvascular narrowing, thrombosis and vasoplegia.
13. The core principles of the pulmonary phase (MATH+) is the use of anti-inflammatory agents to dampen the “cytokine storms” together with full anticoagulation to limit the microvascular and macrovascular clotting and supplemental oxygen to help overcome the hypoxia.
14. Ivermectin has emerged as the “*wonder drug*” to prophylaxis and treat COVID-19. Ivermectin inhibits viral replication and has potent anti-inflammatory properties. Emerging clinical data (including RCT’s) suggest that ivermectin may have an important clinical benefit across the spectrum of phases of the disease, i.e pre-exposure prophylaxis, postexposure prophylaxis, during the symptomatic phase and during the pulmonary phase. [1-3,67,70-77,134-136,187-194] In the recommended dosages, Ivermectin is remarkably safe (see Table 1 and Fig 5). However, as noted above there is the potential for serious drug-drug interaction.
15. The pulmonary phase of COVID-19 is characterized by PROLONGED immune dysregulation that may last weeks or even months. The early and abrupt termination of anti-inflammatory agents will likely result in rebound inflammation (see Figure 8).[316]
16. SARS-CoV-2 as compared to all other respiratory viruses, upregulates cytokines and chemokines while at the same time down regulating the expression of Interferon alpha (the hosts primary antiviral defence mechanism). [131,155] Low innate antiviral defenses and high pro-inflammatory mediators contribute to ongoing and progressive lung injury.
17. Patients in whom the cytokine storm is not “dampened” will progress into the “H phenotype” characterized by poor lung compliance, severe oxygenation failure and PEEP recruitability (see Figure 9). Progression to this phase is exacerbated by ventilator induced lung injury (VILI). The histologic pattern of the “H Phenotype” is characterized by an acute fibrinous and organizing pneumonia (AFOP), with extensive intra-alveolar fibrin deposition called fibrin “balls” with absent or minimal hyaline membranes.[289,311,317-319] Corticosteroids seem to be of little benefit in established AFOP. High dose methylprednisolone should be attempted in the “early phase” of AFOP, however many patients will progress to irreversible pulmonary fibrosis with prolonged ventilator dependency and ultimately death.
18. An unknown percentage of patients with COVID-19 present with “silent hypoxia” with a blunted respiratory response. This phenomenon may be related to involvement of chemoreceptors of the carotid bodies and/or brain stem dysfunction,[320,321] and necessitates pulse oximetry in symptomatic patients managed at home (as discussed above).
19. It should be recognized that LWMH has non-anticoagulant properties that are likely beneficial in patients with COVID-19, these include anti-inflammatory effects and inhibition of histones.[322] in addition, in vitro studies demonstrate that heparin inhibits SARS-CoV-2 interaction with the ACE-2 receptor and viral entry,[323,324] as well as viral replication [75,138]. Most importantly LWWH inhibits heparanase (HPSE).[325] HSE destroys the endothelial glycocalyx increasing endothelial leakiness, activating clotting and potentiating endothelialitis.[325] HPSE levels have been reported to be increased in patients with severe COVID-19 infection. [326]
20. Due to the ease of administration, greater anti-Xa activity and better safety profile we prefer low molecular weight heparin (LMWH) to unfractionated heparin (UFH).
21. The combination of steroids and ascorbic acid (vitamin C) is essential. Both have powerful synergistic anti-inflammatory actions. [173,181] Vitamin C protects the endothelium from oxidative injury.[174,327-329] Furthermore, vitamin C increases the expression of interferon-

alpha [26] while corticosteroids (alone) decrease expression of this important protein. [330-333] It should be noted that when corticosteroids are used in the pulmonary phase (and not in the viral replicative phase) they do not appear to increase viral shedding or decrease the production of type specific antibodies. [159,334] It is likely that heparin (LMWH) acts synergistically with corticosteroids and vitamin C to protect the endothelium and treat the endothelialitis of severe COVID-19 disease.

22. Notwithstanding the very important and impressive results of the Recovery-Dexamethasone study, methylprednisolone is the corticosteroid of choice for the pulmonary phase of COVID-19. This is based on pharmacokinetic data (better lung penetration),[335] genomic data specific for SARS-CoV-2,[336] and a long track record of successful use in inflammatory lung diseases. (see Table 1)
23. For prophylaxis and treatment of the early symptomatic phase we suggest the combination of Quercetin (a plant polyphenol), Vitamin C and Zinc.[35] This is based on intriguing basic science data which indicates that:
  - a. Zinc is essential for innate and adaptive immunity.[52] In addition, Zinc inhibits RNA dependent RNA polymerase *in vitro* against SARS-CoV-2 virus.[51]
  - b. Quercetin has direct viricidal properties against a range of viruses, including SARS-CoV-2, and is a potent antioxidant and anti-inflammatory agent. [24,29,34,34,337-344] In addition, quercetin acts as a zinc ionophore. [345]
  - c. Vitamin C improves the potency of Quercetin and has antiviral and anti-inflammatory activity.[24]
24. It should also be noted that Vitamin D may be an enormously powerful prophylactic strategy against COVID-19. Vitamin D deficiency explains, in part, the enormous geographic variation in mortality of this disease. [11,346] It is likely that vitamin D supplementation may have a greater role in the prophylaxis than the treatment of severe disease.



**Figure 9. The consequences of “steroid” avoidance”. CT scan after 23 days of “supportive care” demonstrating the late fibroproliferative (irreversible) phase of COVID-19 lung disease (Image kindly provide by Dr. Pierre Kory, from NYC).**



## Scientific Rationale for MATH+ Treatment Protocol (pulmonary phase)

Three core pathologic processes lead to multi-organ failure and death in COVID-19:

- 1) **Hyper-inflammation (“Cytokine storm”)** – a dysregulated immune system whose cells infiltrate and damage the lungs as well as other organs including the heart and bone marrow. It is now widely accepted that SARS-CoV-2 causes aberrant T lymphocyte and macrophage activation resulting in a “cytokine storm.” [247,249,260,261,287,295,297-303] In addition, post-mortem examination has demonstrated features of the “macrophage activation syndrome”, with hemophagocytosis and a hemophagocytic lymphohistiocytosis-like disorder.[257]
- 2) **Hyper-coagulability (increased clotting)** – the dysregulated immune system damages the endothelium and activates blood clotting, causing the formation of micro and macro blood clots. Clotting activation may occur directly due to increased expression of Factor Xa as well as endothelial injury with the release of large aggregates of van Willebrand factor.[81] These blood clots impair blood flow. [139,140,142-150,306,307,347,348] It should be noted that the thrombotic microangiopathy appears to target predominantly the pulmonary and cerebral circulation. [257]
- 3) **Severe Hypoxemia (low blood oxygen levels)** –lung inflammation caused by the cytokine storm, together with microthrombosis in the pulmonary circulation severely impairs oxygen absorption resulting in oxygenation failure.

The above pathologies are not novel, although the combined severity in COVID-19 disease is considerable. Our long-standing and more recent experiences show consistently successful treatment if traditional therapeutic principles of **early and aggressive intervention** is achieved, before the onset of advanced organ failure. It is our collective opinion that the historically high levels of morbidity and mortality from COVID-19 is due to a single factor: the widespread and inappropriate reluctance amongst hospitalists and intensivists to employ anti-inflammatory and anticoagulant treatments, including corticosteroid therapy *early in the course of a patient’s hospitalization*. It is essential to recognize that it is not the virus that is killing the patient, rather it is the patient’s overactive immune system. [246,249,257,321] Autopsy studies have demonstrated minimal viral cytopathic effects.[257,321] The flames of the “cytokine fire” are out of control and need to be extinguished. Providing supportive care (with ventilators that themselves stoke the fire) and waiting for the cytokine fire to burn itself out simply does not work... this approach has FAILED and has led to the death of tens of thousands of patients.

**“If what you are doing ain’t working, change what you are doing” – PEM**

The systematic failure of critical care systems to adopt corticosteroid therapy (early in this pandemic) resulted from the published recommendations against corticosteroids use by the World Health Organization (as recent as May 27<sup>th</sup> 2020) [349,350]. This recommendation was then perpetuated by the Centers for Disease Control and Prevention (CDC), the American Thoracic Society (ATS), Infectious Diseases Association of America (IDSA) amongst others. A publication authored one of the members of the Front Line COVID-19 Critical Care (FLCCC) Alliance (UM), identified the errors made by these organizations in their analyses of corticosteroid studies based on the findings of the SARS and H1N1 pandemics.[154,351] Their erroneous recommendation to avoid corticosteroids in the treatment of COVID-19 has led to the development of myriad organ failures which have overwhelmed critical care systems across the world and led to excess deaths. The recently published results of the RECOVERY-DEXAMETHASONE study provide definitive and unambiguous evidence of the lifesaving benefits of corticosteroids and strong validation of the MATH + protocol. It should be recognized that corticosteroids are the only therapy proven to reduce the mortality in patients with COVID-19.[352] The



RECOVERY-DEXAMETHASONE study, randomized 2104 patients to receive dexamethasone 6 mg (equivalent to 32 mg methylprednisolone) once per day (either by mouth or by intravenous injection) for ten days and were compared with 4321 patients randomized to usual care alone.[128] Dexamethasone reduced deaths by one-third in ventilated patients (rate ratio 0.65 [95% confidence interval 0.48 to 0.88]; p=0.0003) and by one fifth in other patients receiving oxygen only (0.80 [0.67 to 0.96]; p=0.0021). There was no benefit among those patients who did not require respiratory support (1.22 [0.86 to 1.75; p=0.14). The results of this study STRONGLY support the EVMS/MATH+ protocol which recommends the use of corticosteroids for the “pulmonary phase” of COVID-19. It should be noted that we would consider the non-titratable “fixed” dose of dexamethasone used in the RECOVERY-DEXAMETHASONE study to be very low. Furthermore, as indicated above we consider methylprednisolone to be the corticosteroid of choice for the treatment of COVID-19 pulmonary disease. The benefit of methylprednisolone in improving respiratory function, ventilator dependency and mortality has been confirmed in a number of observational studies, [155,156,162,334,353-355] as well as a randomized controlled study.[164] It should be recognized that the mortality benefit with methylprednisolone was not replicated in a recent Brazilian RCT. [316] However, in this study methylprednisolone was started relatively late (day 13 after symptom onset), but most importantly was stopped on day 5. This failed study reinforces the concept of early and prolonged treatment with methylprednisolone titrated to the patient’s clinical response. In patients at high risk of Strongyloides infection, screening and/or treatment of this parasite with ivermectin is suggested prior to treatment with corticosteroids.[356]

Our treatment protocol targeting the key pathologic processes has been highly successful, *if begun within 6 hours* of a COVID19 patient presenting with shortness of breath and/or arterial desaturation and requiring supplemental oxygen. If such early initiation of treatment could be systematically achieved, the need for mechanical ventilators and ICU beds will decrease dramatically.

**Further resources:**

The reader is referred to the large autopsy series by Bruce and colleagues which clearly outlines the pathophysiology of severe COVID-19 disease.[257]

The scientific rationale for the MATH + protocol is reviewed in this paper.[171]

In this U-tube video, Professor Britt Glaunsinger, PhD provides an outstanding review on the molecular virology of SARS-CoV-2: <https://www.youtube.com/watch?v=DQVpHyvz4no>

Lectures by Paul Marik, MD reviewing clinical aspects of COVID-19.  
<https://www.youtube.com/channel/UCz9Pvn15m4Rv1uY-aBYRVuw>

## References

1. Gorial FI, Mashhadani S, Sayaly HM et al. Effectiveness of Ivermectin as add-on therapy in COVID-19 management (Pilot Trial). medRxiv 2020.
2. Khan MS, Khan MS, Debnath Cr et al. Ivermectin treatment may improve the prognosis of patients with COVID-19. Archivos de Bronconeumologia 2020.
3. Rajter JC, Sherman MS, Fatteh N et al. ICON (Ivermectin in COvid Ninteen) study: Use of ivermectin is associated with lower mortality in hospitalized patients with COVID-19. Chest 2020.
4. Niaee MS, Gheibl N, Namdar P et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial. Research Square 2020.
5. Elgazzar A, Hany B, Youssef SA et al. Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic. Research Square 2020.
6. Hashim HA, Maulood MF, rasheed AM et al. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Bagdad, Iraq. medRxiv 2020.
7. Maghbooli Z, Sahraian MA, Ebrahimi M et al. Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/ml reduced risk for adverse clinical outcomes in patients with COVID-19 infection. PloS ONE 2020; 15:e0239799.
8. Grant WB, Lahore H, McDonnell SL et al. Evidence that Vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients 2020; 12:988.
9. Kaufman HW, Niles JK, Kroll MH et al. SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D level. PloS ONE 2020; 15:e0239252.
10. Lau FH, Majumder R, Torabi R et al. Vitamin D insufficiency is prevalent in severe COVID-19. medRxiv 2020.
11. Marik PE, Kory P, Varon J. Does vitamin D status impact mortality from SARS-CoV-2 infection? Medicine in Drug Discovery 2020.
12. Rhodes JM, Subramanian S, Laird E et al. Editorial: Low population mortality from COVID-19 in countries south of 35 degrees North - supports vitamin D as a factor determining severity. Alimentary Pharmacology & Therapeutics 2020; (in press).
13. Dancer RC, Parekh D, Lax S et al. Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). Thorax 2015; 70:617-24.
14. Llie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clin Exp Res 2020.
15. Daneshkhan A, Eshein A, Subramanian H. The role of vitamin D in suppressing cytokine storm of COVID-19 patients and associated mortality. medRxiv 2020.
16. Bergman P, Lindh AU, Bjorkhem-Bergman L et al. Vitamin D and respiratory tract infections: A systematic review and meta-analysis of randomized controlled trials. PloS ONE 2013; 8:e65835.
17. Carpagnano GE, Lecce V, Quaranta VN et al. Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. J Endocrinol Invest 2020.
18. Israel A, Cicurel A, Feldhamer I et al. The link between vitamin D deficiency and Covid-19 in a large population. medRxiv 2020.
19. Radujkovic A, Hippchen T, Tiwari-Heckler S et al. Vitamin D deficiency and outcome of COVID-19 patients. Nutrients 2020; 12:2757.
20. Rizzoli R. Vitamin D supplementation: upper limit for safety revisited. Aging Clin Exp Res 2020.
21. Annweiler C, Hanotte B, de L'Eprevier CG et al. Vitamin D and survival in COVID-19 patients: A quasi-experimental study. Journal of Steroid Biochemistry & Molecular Biology 2020.
22. Moozhipurath RK, Kraft L, Skiera B. Evidence of protective role of Ultraviolet-B (UVB) radiation in reducing COVID-19 deaths. Nature Research 2020; 10:17705.
23. Maggini S, Beveridge S, suter M. A combination of high-dose vitamin C plus zinc for the common cold. Journal of International Medical Research 2012; 40:28-42.
24. Colunga Biancatelli RM, Berrill M, Catravas JD et al. Quercetin and Vitamin C: experimental therapy for the prevention and treatment of SARS-CoV-2 via synergistic action. Front Immunol 2020.
25. Kyung Kim T, Lim HR, Byun JS. Vitamin C supplementaion reduces the odds of developing a common cold in Republic of Korea Army recruits: a randomised controlled trial. BMJ Mil Health 2020.
26. Colunga Biancatelli RM, Berrill M, Marik PE. The antiviral properties of vitamin C. Expert Rev Anti Infect Ther 2020; 18:99-101.

27. Hiedra R, Lo KB, Elbashesheh M et al. The use of IV vitamin C for patients with COVID-19: a case series. *Exp Rev Anti Infect Ther* 2020.
28. Khaerunnisa S. Potential inhibitor of COVID-19 main protease (Mpro) from several medicinal plant compuns by molecular docking study. medRxiv 2020.
29. Chen L, Li J, Luo C et al. Binding interaction of quercetin-3-B-galactoside and its synthetic derivatives with SARS-CoV 3CL: structure-activity relationship reveal salient pharmacophore features. *Bioorganic & Medicinal Chemistry Letters* 2006; 14:8295-306.
30. Nain Z, Rana HK, Lio P et al. Pathogenic profiling of COVID-19 and SARS-like viruses. *Briefings in Bioinformatics* 2020.
31. Yi L, Li Z, Yuan K et al. Small molecules blocking the entry of severe respiratory syndrome coronavirus into host cells. *J Virol* 2020; 78:11334-39.
32. Shakoor H, Feehan J, Dhaheri AS et al. Immune-boosting role of vitamins D,C,E, zinc, selenium and omega-3 fatty acids: could they help against COVID-19. *Maturitas* 2020.
33. Calder PC. Nutrition, immunity and COVID-19. *BMJ Nutrition, Prevention & Health* 2020; 3.
34. Abian O, Ortega-Alarcon D, Jimenez-Alesanco A et al. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening. *International Journal of Biological Macromolecules* 2020; 164:1693-703.
35. Arslan B, Ergun NU, Topuz S et al. Synergistic effect of quercetin and vitamin C against COVID-19: Is a possible guard for front liners? *ssrn* 2020.
36. Giuliani C, Bucci I, Di Santo S et al. The flavonoid quercetin in hibits thyroid-restricted genes expression and thyroid function. *Food and Chemical Toxicology* 2014; 66:23-29.
37. de Souza dos Santos MC, Goncalves CF, Vaisman M et al. Impact of flavonoids on thyroid function. *Food and Chemical Toxicology* 2011; 49:2495-502.
38. Chandra AK, De N. Catechin induced modulation in the activities of thyroid hormone synthesizing enzymes leading to hypothyroidism. *Mol Cell Biochem* 2013; 374:37-48.
39. Pistollato F, Masias M, Agudo P et al. Effects of phytochemicals on thyroid function and their possible role in thyroid disease. *Ann N Y Acad Sci* 2019; 1433:3-9.
40. Sathyapalan T, Manuchehri AM, Thatcher NJ et al. The effect of soy phytoestrogen supplementation on thyroid status and cardiovascular risk markers in patients with subclinical hypothyroidism: A randomized, double-blind, crossover study. *J Clin Endocrinol Metab* 2020; 96:1422-49.
41. Tonstad S, Jaceldo-Siegl K, Messina M et al. The association between soya consumption and serum thyroid-stimulating hormone in the Adventist Health Study-2. *Public Health Nutr* 2016; 19:1464-70.
42. Colombo D, Lunardon L, Bellia G. Cyclosporine and herbal supplement interactions. *Journal of Toxicology* 2014; 2014:145325.
43. Colunga Biancatelli RM, Berrill M, Mohammed YH et al. Melatonin for the treatment of sepsis: the scientific rationale. *J Thorac Dis* 2020; 12 (Suppl 1):S54-S65.
44. Reiter RJ, Abreu-Gonzalez P, Marik PE et al. Therapeutic algorithm for use of melatonin in patients with COVID-19. *Front Med* 2020; 7:226.
45. Reiter RJ, Sharma R, Ma Q et al. Melatonin inhibits COVID-19-induced cytokine storm by reversing aerobic glycolysis in immune cells: A mechanistic analysis. *Medicine in Drug Discovery* 2020; 6:100044.
46. Zhang R, Wang X, Ni L et al. COVID-19: Melatonin as a potential adjuvant treatment. *Life Sci* 2020; 250:117583.
47. Jehi L, Ji X, Milinovich A et al. Individualizing risk prediction for positive COVID-19 testing. Results from 11,672 patients. *Chest* 2020.
48. Kleszczynski K, Slominski AT, Steinbrink K et al. Clinical trials for use of melatonin to fight COVID-19 are urgently needed. *Nutrients* 2020; 12.
49. Coto-Montes A, Boga JA. ER stress and autophagy induced by SARS-CoV-2: The targer for melatonin treatment. *Melatonin Res* 2020; 3:346-61.
50. Gandolfi JV, Di Bernardo AP, Chanes DA et al. The effects of melatonin supplementation on sleep quality and assessment of the serum melatonin in ICU patients: A randomized controlled trial. *Crit Care Med* 2020.
51. te Velthuis AJ, van den Worm SH, Sims AC et al. Zn<sup>2+</sup> inhibits Coronavirus and Arterivirus RNA polymerase activity In Vitro and Zinc ionophores block the replication of these viruses in cell culture. *PLoS Pathog* 2010; 6:e1001176.
52. Gammoh NZ, Rink L. Zinc in Infection and Inflammation. *Nutrients* 2017; 9.

53. Hemila H. Zinc lozenges and the common cold: a meta-analysis comparing zinc acetate and zinc gluconate, and the role of zinc dosage. *J Royal Soc Med Open* 2017; 8:1-7.
54. Singh M, Das RR. Zinc for the common cold. *Cochrane Database of Syst Rev* 2013; 6:CD001364.
55. Hoeger J, Simon TP, Beeker T et al. Persistent low serum zinc is associated with recurrent sepsis in critically ill patients - A pilot study. *PLoS ONE* 2017; 12:e0176069.
56. Shakoor H, Freehan J, Mikkelsen K et al. Be well: A potential role for vitamin B in COVID-19. *Maturitas* 2020.
57. dos Santos LM. Can vitamin B12 be an adjuvant to COVID-19 treatment? *GSC Biological and Pharmaceutical Sciences* 2020; 11.
58. Kandeel M, Al-Nazawi M. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. *Life Sci* 2020; 251:117627.
59. Tan CW, Ho LP, Kalimuddin S et al. Cohort study to evaluate effect of vitamin D, magnesium, and vitamin b12 in combination on severe outcome progression in older patients with coronavirus (COVID-19). *Nutrition* 2020; 80:111017.
60. Zhang P, Tsuchiya K, Kinoshita T et al. Vitamin B6 prevents IL-1B protein production by inhibiting NLRP3 inflammasome activation. *J Biol Chem* 2020; 291:24517-27.
61. Behera P, Patro BK, Singh AK et al. Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study. *medRxiv* 2020.
62. Carvallo H, Hirsch RR, Alkis P et al. Study of the efficacy and safety of topical ivermectin + Iota-carrageenan in the prophylaxis against COVID-19 in health personnel. *Journal of Biomedical Research and Clinical Investigation* 2020; 2.
63. Kory P, Meduri GU, Iglesias J et al. Review of the emerging evidence supporting the use of Ivermectin in the prophylaxis and treatment of COVID-19. *Front Line Covid-19 Critical Care Alliance*. *osf io* 2020.
64. Hellwig MD, Maia A. A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin. *Int J Antimicrob Agents* 2020.
65. Munoz J, Ballester MR, Antonijoan RM et al. Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers. *PLoS Neglected Tropical Diseases* 2018; 12:e0006020.
66. Castillo ME, Costa LM, Barrios JM et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. *J Steroid Biochem Mol Biol* 2020.
67. Hashim HA, Maulood MF, rasheed AM et al. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq. *medRxiv* 2020.
68. Alam MT, Murshed R, Bhiuyan E et al. A case series of 100 COVID-19 positive patients treated with combination of Ivermectin and Doxycycline. *Bangladesh Coll Phys Surg* 2020; 38:10-15.
69. Chowdhury AT, Shahabz M, Karim MR et al. A randomized trial of ivermectin-doxycycline and hydrochloroquine-azithromycin therapy on COVID-19 patients. *Research Square* 2020.
70. Chamie J. Real-World evidence: The case of Peru, casualty between Ivermectin and COVID-19 infection fatality rate. *ResearchGate* 2020.
71. Caly L, Druce JD, Catton MG et al. The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res* 2020.
72. Lehrer S, Rheinstein PH. Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2. *In Vivo* 2020; 34:3023-26.
73. Maurya DK. A combination of Ivermectin and Doxycycline possibly blocks the viral entry and modulate the innate immune response in COVID-19 patients. *ChemRxiv* 2020.
74. Yang SN, Atkinson SC, Wang C et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin alpha/beta1 heterodimer. *Antiviral Res* 2020; 177:104760.
75. Dayer MR. Coronavirus (2019-nCoV) deactivation via spike glycoprotein shielding by old drugs, bioinformatic study. *Preprints* 2020.
76. Swargiary A. Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: Evidence from silico studies. *Research Square* 2020.
77. Kircik LH, Del Rosso JQ, Layton AM et al. Over 25 years of clinical experience with Ivermectin: An overview of safety for an increasing number of indications. *J Drugs Dermatol* 2016; 15:325-32.
78. Kalfas S, Visvanathan K, Chan K et al. The therapeutic potential of ivermectin for COVID-19: A systematic review of mechanisms and evidence. *medRxiv* 2020.

79. Bianconi V, Violi F, Fallarino F et al. Is acetylsalicylic acid a safe and potentially useful choice for adult patients with COVID-19? *Drugs* 2020.
80. Muller C, Karl N, Ziebuhr J et al. D,L-lysine acetylsalicylate + glycine impairs coronavirus replication. *J Antivir Antiretrovir* 2020.
81. Varatharajah N. COVID-19 CLOT: What is it? Why in the lungs? Extracellular histone, "auto-activation" of prothrombin, emperipolesis, megakaryocytes, "self-association" of Von Willebrand factor and beyond. *Preprints* 2020.
82. Freedberg DE, Conigliaro J, Sobieszczyk ME et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. *medRxiv* 2020.
83. Janowitz T, Baglenz E, Pattinson D et al. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalized patients: a case series. *Gut* 2020; 69:1592-97.
84. Mather JF, Seip RL, McKay RG. Impact of famotidine use on clinical outcomes of hospitalized COVID-19 patients. *Am J Gastroenterol* 2020.
85. Malone RW, Tisdall P, Fremont-Smith P et al. COVID-19: Famotidine, Histamine, Mast Cells, and mechanisms. *Research Square* 2020.
86. Sethia R, Prasad M, Mahapatra SJ et al. Efficacy of famotidine for COVID-19: A systematic review and meta-analysis. *medRxiv* 2020.
87. Shoaibi A, Fortin S, Weinstein R et al. Comparative effectiveness of famotidine in hospitalized COVID-19 patients. *medRxiv* 2020.
88. Yeramaneni S, Doshi P, Sands K et al. Famotidine use is not associated with 30-day mortality: A coarsened exact match study in 7158 hospitalized COVID-19 patients from a large healthcare system. *medRxiv* 2020.
89. Hammock BD, Wang W, Gilligan MM et al. Eicosanoids. The overlooked storm in Coronavirus Disease 2019 (COVID-19)? *Am J Pathol* 2020.
90. Das UN. Can bioactive lipids inactivate coronavirus (COVID-19)? *Arch Med Res* 2020; 51:282-86.
91. Lee CR, Zeldin DC. Resolvin infectious inflammation by targeting the host response. *N Engl J Med* 2015; 373:2183-85.
92. Serhan CN. Novel pro-resolving lipid mediators in inflammation are leads for resolution physiology. *Nature* 2014; 510:92-101.
93. Idelsis Esquivel-Moynelo I, Perez-Escribano J, Duncan-Roberts Y et al. Effect of combination of interferon alpha-2b and interferon-gamma or interferon alpha 2b alone for elimination of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial. *medRxiv* 2020.
94. Davoudi-Monfarad E, Rahmani H, Khalili H et al. Efficacy and safety of interferon B-1a in treatment of severe COVID-19: A randomized clinical trial. *medRxiv* 2020.
95. Wang N, Zhan Y, Zhu L et al. Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients. *Cell Host & Microbe* 2020;ePub.
96. Meng Z, Wang T, Chen L et al. An experimental trial of recombinant human interferon alpha nasal drops to prevent COVID-19 in medical staff in an epidemic area. *medRxiv* 2020.
97. Berg K, Bolt G, Andersen H et al. Zinc potentiates the antiviral action of human IFN-alpha tenfold. *J Interferon Cytokine Res* 2001; 21:471-74.
98. Cakman I, Kirchner H, Rink L. Zinc supplementation reconstitutes the production of interferon-alpha by leukocytes from elderly persons. *J Interferon Cytokine Res* 1997; 17:469-72.
99. Luks AM, Swenson ER. Pulse oximetry for monitoring patients with COVID-19 at home: Potential pitfalls and practical guidance. *Ann Thorac Med* 2020.
100. Jouffroy R, Jost D, Prunet B. Prehospital pulse oximetry: a red flag for early detection of silent hypoxemia in COVID-19 patients. *Crit Care* 2020; 24:313.
101. Risch HA. Early outpatient treatment of symptomatic, High-Risk Covid-19 patients that should be ramped-up immediately as key to the pandemic crisis. *Am J Epidemiol* 2020.
102. Borba MG, Val FF, Sampaio S. Effect of High vs Low Doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A randomized clinical trial. *JAMA Network Open* 2020.
103. Boulware DR, Pullen MF, Bangdiwala AS et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. *N Engl J Med* 2020.
104. Barnabas RV, Brown ER, Bershteyn A et al. Hydroxychloroquine as postexposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 infection. *Ann Intern Med* 2020.

105. Mitja O, Corbacho-Monne M, Ubals M et al. Hydroxychloroquine for early treatment of adults with mild Covid-19: A randomized-controlled trial. *Clin Infect Dis* 2020.
106. Mitja O, Ubals M, Corbach-Monne M et al. A cluster-randomized trial of hydroxychloroquine as prevention of Covid-19 transmission and disease. *N Engl J Med* 2020.
107. Cavalcanti AB, Zampieri FG, Rosa RG et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. *N Engl J Med* 2020; 383:2041-52.
108. Skipper CP, Pastick KA, Engen NW. Hydroxychloroquine in nonhospitalized adults with early COVID-19. *Ann Intern Med* 2020; 173:623-31.
109. Rosenberg ES, Dufort EM, Udo T et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. *JAMA* 2020; 323:2493-502.
110. Geleris J, Sun Y, Platt J et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. *N Engl J Med* 2020.
111. Magagnoli J, Narendran S, Pereira F. Outcomes of hydroxychloroquine usage in United states veterans hospitalized with COVID-19. *medRxiv* 2020.
112. Lopez A, Duclos G, Pastene B et al. Effects of hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results. *Int J Antimicrob Agents* 2020.
113. Mahevas M, Tran VT, Roumier M et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial. *medRxiv* 2020.
114. Elsayah HK, Elsayah MA, Elrazaz MG et al. Hydroxychloroquine for treatment of non-severe COVID-19 patients: systematic review and meta-analysis of controlled clinical trials. *medRxiv* 2020.
115. Axfors C, Schmitt AM, Janiaud P et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials. *medRxiv* 2020.
116. Sbidian E, Josse J, Lemaitre G et al. Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France. *medrx* 2020.
117. Effect of hydroxychloroquine in hospitalized patients with COVID-19. *N Engl J Med* 2020; 383:2030-2040.
118. Abd-El Salam S, Esmail ES, Khalaf M et al. Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study. *Am J Trop Med Hyg* 2020; 103:1635-39.
119. Rajasingham R, Bangdiwala AS, Nicol MR et al. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. *medRxiv* 2020.
120. Self WE, Semler MW, Leither LM et al. Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19. a randomized clinical trial. *JAMA* 2020.
121. Tett SE, Cutler DJ, Day RO et al. Bioavailability of hydroxychloroquine tablets in healthy volunteers. *Br J Clin Pharmacol* 1989; 27:771-79.
122. MacGowan A, Hamilton F, Bayliss M et al. Hydroxychloroquine serum concentrations in non-critical care patients infected with SARS-CoV-2. *medRxiv* 2020.
123. Nicol MR, Joshi A, Rizk ML et al. Pharmacokinetic and pharmacological properties of chloroquine and hydroxychloroquine in the context of COVID-19 infection. *medRxiv* 2020.
124. Gautret P, Lagier JC, Parola P et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents* 2020.
125. Lagier JC, Million M, Gautret P et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis. *Travel Medicine and Infectious Disease* 2020.
126. Million M, Gautret P, Colson P et al. Clinical efficacy of chloroquine derivatives in COVID-19 infection: Comparative meta-analysis between big data and the real world. *New Microbes and New Infections* 2020.
127. Morgan A, Stevens J. Does *Bacopa monnieri* improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. *J Altern Complement Med* 2010; 16:753-59.
128. Effect of Dexamethasone in hospitalized patients with COVID-19-Preliminary report. *N Engl J Med* 2020.
129. Schultze A, Walker AJ, MacKenna B et al. Inhaled corticosteroids use and the risk of COVID-19 related death among 966,461 patients with COPD or asthma: An OpenSAFELY analysis. *medRxiv* 2020.
130. Quesada-Gomez JJ, Bouillon R. Is calcifediol better than cholecalciferol for vitamin D supplementation? *Osteoporosis International* 2018; 29:1697-711.
131. Cesareo R, Falchetti A, Attanasio R et al. Hypovitaminosis D: Is it time to consider the use of calcifediol? *Nutrients* 2019; 11:1016.

132. Early high-dose vitamin D3 for critically ill, vitamin D-deficient patients. *N Engl J Med* 2019; 381:2529-40.
133. Amrein K, Martucci G, McNALLY JD. When not to use meta-analysis: Analysing the meta-analysis on vitamin D in critical care. *Clin Nutr* 2017; 36:1729-30.
134. Zhang X, Song Y, Ci X et al. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. *Inflamm Res* 2008; 57:524-29.
135. Ci X, Li H, Yu Q et al. Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen activated protein kinase pathway. *Fundamental & Clinical Pharmacology* 2009; 23:449-55.
136. DiNicolantonio JJ, Barroso-Arranda J, McCarty M. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. *Open Heart* 2020; 7:e001350.
137. Hsu A, Liu Y, Zayac AS et al. Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia. *Thrombosis Research* 2020.
138. Kwon PS, Oh H, Kwon SJ et al. Sulphated polysaccharides effectively inhibit SARS-CoV-2 in vitro. *Cell Discovery* 2020; 6:50.
139. Bikdeli B, Madhavan MV, Jimenez et al. COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up. *J Am Coll Cardiol* 2020.
140. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. *Blood* 2020.
141. Nadkarni GN, Lala A, Bagiella E et al. Anticoagulation, mortality, bleeding and pathology among patients hospitalized with COVID-19: A single Health System Study. *J Am Coll Cardiol* 2020.
142. Klok FA, Kruip MJ, van der Meer NJ et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thrombosis Research* 2020.
143. Zhai Z, Li C, Chen Y et al. Prevention and treatment of venous thromboembolism associated with Coronavirus Disease 2019 Infection: A consensus statement before guidelines. *Thromb Haemost* 2020.
144. Paranjpe I, Fuster V, Lala A et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. *J Am Coll Cardiol* 2020.
145. Iba T, Levy JH, Levi M et al. Coagulopathy of coronavirus disease 2019. *Crit Care Med* 2020.
146. Joly BS, Siguret V, Veyradier A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. *Intensive Care Med* 2020; 46:1603-6.
147. Helms J, Tacquard C, Severac F et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. *Intensive Care Med* 2020; 46:1089-98.
148. Varatharajah N, Rajah S. Microthrombotic complications of COVID-19 are likely due to embolism of circulating endothelial derived ultralarge Von Willebrand Factor (eULVWF) decorated-platelet strings. *Federal Practitioner* 2020.
149. Du L, Kao RY, Zhou Y et al. Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity. *Biochemical & Biophysical Research Communications* 2007; 359:174-79.
150. Taccone FS, Gevenois PA, Peluso L et al. Higher intensity thromboprophylaxis regimens and pulmonary embolism in critically ill coronavirus disease 2019 patients. *Crit Care Med* 2020.
151. Hottz ED, Azevedo-Quintanilha Ig, Palhinha L et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. *Blood* 2020; 136:1330-1341.
152. Barrett TJ, Lee AH, Xia Y et al. Platelet and vascular biomarkers associate with thrombosis and death in coronavirus disease. *Circulation Research* 2020; 127:945-47.
153. Zhang S, Liu Y, Wang X et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. *Journal of hematology & oncology* 2020; 13:120.
154. Villar J, Confalonieri M, Pastores SM et al. Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome (ARDS) caused by COVID-19. *Crit Care Expl* 2020; 2:e0111.
155. Fadel R, Morrison AR, Vahia A et al. Early course corticosteroids in hospitalized patients with COVID-19. *Clin Infect Dis* 2020; 71:2114-20.
156. Chroboczek T, Lacoste M, Wackenheim C et al. Beneficial effect of corticosteroids in severe COVID-19 pneumonia: a propensity score matching analysis. *medRxiv* 2020.
157. Wu C, Chen X, Cai Y et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med* 2020.
158. Cruz AF, Ruiz-Antoran B, Gomez AM et al. Impact of glucocorticoid treatment in SARS-CoV-2 infection mortality: A retrospective controlled cohort study. *medRxiv* 2020.
159. Liu J, Zheng X, Huang Y et al. Successful use of methylprednisolone for treating severe COVID-19. *J Allergy Clin Immunol* 2020.

160. Meduri GU, Bridges L, Shih MC et al. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature. *Intensive Care Med* 2016; 42:829-40.
161. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19. A meta-analysis. *JAMA* 2020.
162. Ruiz-Irastorza G, Pijoan JI, Bereciatua E et al. Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data. *medRxiv* 2020.
163. Tomazini BM, Maia IS, Cavalcanti AB et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19. The CoDEX randomized clinical trial. *JAMA* 2020.
164. Edalatifard M, Akhtari M, Salehi M et al. Intravenous methylprednisolone pulse as a treatment for hospitalized severe COVID-19 patients: results from a randomised controlled clinical trial. *Eur Respir J* 2020.
165. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19. The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. *JAMA* 2020.
166. Dequin PF, Heming N, Meziani F et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19. A randomized Clinical trial. *JAMA* 2020.
167. Wang Y, Zhang D, Du G et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicenter trial. *Lancet* 2020; 395:1569-78.
168. Beigel JH, Tomashek KM, Dodd LE et al. Remdesivir for the treatment of Covid-19-Preliminary report. *N Engl J Med* 2020;ePub.
169. Spinner CD, Gottlieb RL, Criner GJ et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19. A randomized clinical trial. *JAMA* 2020.
170. Pan H, Peto R, Karim QA et al. Repurposed antiviral drugs for COVID-19 - interim WHO SOLIDARITY trial. *medrx* 2020.
171. Marik PE, Kory P, Varon J et al. MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale. *Exp Rev Anti Infect Ther* 2020.
172. Marik PE, Khangoora V, Rivera R et al. Hydrocortisone, Vitamin C and Thiamine for the treatment of severe sepsis and septic shock: A retrospective before-after study. *Chest* 2017; 151:1229-38.
173. Barabutis N, Khangoora V, Marik PE et al. Hydrocortisone and Ascorbic Acid synergistically protect and repair lipopolysaccharide-induced pulmonary endothelial barrier dysfunction. *Chest* 2017; 152:954-62.
174. Marik PE. Hydrocortisone, Ascorbic Acid and Thiamine (HAT therapy) for the treatment of sepsis. *Focus on ascorbic acid. Nutrients* 2018; 10:1762.
175. Marik PE. Vitamin C for the treatment of sepsis: The scientific rationale. *Pharmacol Therapeut* 2018; 189:63-70.
176. Cheng RZ. Can early and high-dose vitamin C prevent and treat coronavirus disease 2019 (COVID-19). *Medicine in Drug Discovery* 2020.
177. Wang Y, Lin H, Lin BW et al. Effects of different ascorbic acid doses on the mortality of critically ill patients: a meta-analysis. *Ann Intensive Care* 2019; 9:58.
178. Fowler AA, Truwit JD, Hite D et al. Vitamin C Infusion for Treatment In Sepsis-Induced Acute Lung Injury-CITRIS-ALI: A Randomized, Placebo Controlled Clinical Trial. *JAMA* 2018; 322:1261-70.
179. Boretti A, Banik BK. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. *PharmaNutrition* 2020; 12:100190.
180. Iglesias J, Vassallo AV, Patel V et al. Outcomes of metabolic resuscitation using ascorbic acid, thiamine, and glucocorticoids in the early treatment of sepsis. *Chest* 2020; 158:164-73.
181. de Melo AF, Homem-de-Mello M. High-dose intravenous vitamin C may help in cytokine storm in severe SARS-CoV-2 infection. *Crit Care* 2020; 24:500.
182. Zhang J, Rao X, Li Y et al. High-dose vitamin C infusion for the treatment of critically ill COVID-19. *Research Square* 2020.
183. Kumari P, Dembra S, Dembra P et al. The role of vitamin C as adjuvant therapy in COVID-19. *Cureus* 2020; 12:e11779.
184. Lankadeva YR, Peiris RM, Okazaki N et al. Reversal of the pathophysiological responses to Gram-negative sepsis by megadose Vitamin C. *Crit Care Med* 2020.



185. Jonmarker S, Hollenberg J, Dahlberg M et al. Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients. medRxiv 2020.
186. Tomasa-Irriguible TM, Martinez-Vega S, Mor-Marco E et al. Low molecular weight heparins in COVID-19 patients: beware of augmented renal clearance! Crit Care 2020; 24:325.
187. Murshed MR, Bhiuyan E, Saber S et al. A case series of 100 COVID-19 positive patients treated with combination of Ivermectin and Doxycycline. Bangladesh Coll Phys Surg 2020; 38:10-15.
188. Patel AN, Desai SS, Grainger DW et al. Usefulness of ivermectin in COVID-19 illness. medRxiv 2020.
189. Jans DA, Wagstaff KM. Ivermectin as a broad-spectrum host directed anti-viral: The real deal. Cells 2020; 9:2100.
190. Sharun K, Dhama K, Patel SK et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob 2020; 19:23.
191. Peralta EG, Fimia-Duarte R, Cardenas JW et al. Ivermectin, a drug to be considered for the prevention and treatment of SARS-CoV-2. Brief literature review. EC Veterinary Science 2020; 5:25-29.
192. Al-Jassim KB, Jawad AA, Al-Masoudi EA et al. Histopathological and biochemical effects of ivermectin on kidney functions, lung and the ameliorative effects of vitamin C in rabbits. Bas J Vet Res 2016; 14:110-124.
193. Mudatsir M, Yufika A, Nainu F et al. Antiviral activity of ivermectin against SARS-CoV-2: an old-fashioned dog with a new trick- Literature review. Sci Pharm 2020; 88:36.
194. Carvallo H, Hirsch R, Farinella ME. Safety and efficacy of the combined use of Ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19. medRxiv 2020.
195. Heaney RP, Armas LA, Shary JR et al. 25-hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. Am J Clin Nutr 2008; 87:1738-42.
196. Murai IH, Fernandes AL, Sales LP et al. Effect of vitamin D3 supplementaion vs placebo on hospital length of stay in patients with severe COVID-19: A multicenter, double-blind, randomized controlled trial. medRxiv 2020.
197. Menezes RR, Godin AM, Rodrigues FF et al. Thiamine and riboflavin inhibit production of cytokines and increase the anti-inflammatory activity of a corticosteroid in a chronic model of inflammation induced by complete Freund's adjuvant. Pharmacological Reports 2020; 69:1036-43.
198. Vatsalya V, Li F, Frimodig J et al. Therapeutic prospects for Th-17 cell immune storm syndrome and neurological symptoms in COVID-19: Thiamine efficacy and safety, In-vitro evidence and pharmacokinetic profile. medRxiv 2020.
199. Mallat J, Lemyze M, Thevenin D. Do not forget to give thiamine to your septic shock patient! J Thorac Dis 2016; 8:1062-66.
200. Moskowitz A, Donnino MW. Thiamine (vitamin B1) in septic shock: a targeted therapy. J Thorac Dis 2020; 12 (suppl 1):S78-S83.
201. Woolum JA, Abner EL, Kelly A et al. Effect of thiamine administration on lactate clearance and mortality in patients with septic shock. Crit Care Med 2018; 46:1747-52.
202. Marik PE. Thiamine: An essential component of the metabolic resuscitation protocol. Crit Care Med 2018; 46:1869-70.
203. Lee CY, Jan WC, Tsai PS et al. Magnesium sulfate mitigates acute lung injury in endotoxemia rats. J Trauma 2011; 70:1177-85.
204. Salem M, Kasinski N, Munoz R et al. Progressive magnesium deficiency increases mortality from endotoxin challenge: Protective effects of acute magnesium replacement therapy [abstract]. Crit Care Med 1995;A260.
205. Jiang P. Does hypomagnesemia impact on the outcome of patients admitted to the intensive care unit? A systematic review and meta-analysis. Shock 2019; 47:288-95.
206. Spoorthi V, Sasank S. Utility of Ivermectin and Doxycycline combination for the treatment of SARS-CoV-2. International Archives of Integrated Medicine 2020; 7.
207. Cloutier N, Allaey I, Marcoux G et al. Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration. PNAS 2018;E1550-E1559.
208. Calfee CS, Delucchi KL, Sinha P et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Resp Med 2018; 6:691-98.
209. Zhang XJ, Qin JJ, Cheng X et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metabolism 2020.

210. Rodriguez-Nava G, Trelles-Garcia DP, Yanez-Bello MA et al. Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study. *Crit Care* 2020; 24:429.
211. Gupta A, Madhavan MV, Poterucha TJ et al. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. *Research Square* 2020.
212. Kow CS, Hasan SS. Meta-analysis of effectiveness of statins in patients with severe COVID-19. *Am J Cardiol* 2020.
213. Tan WY, Young BE, Lye DC et al. Statin use is associated with lower disease severity in COVID-19 infection. *Nature Research* 2020.
214. Oldenburg CE, Doan T. Azithromycin for severe COVID-19. *Lancet* 2020.
215. Futado RH, Berwanger O, Fonseca HA et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised trial. *Lancet* 2020.
216. Agarwal A, Mukherjee A, Kumar G et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). *BMJ* 2020; 371:m3939.
217. Simonovich VA, Pratz LD, Scibona P et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. *N Engl J Med* 2020.
218. Rosas IO, Brau N, Waters M et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. *medRxiv* 2020.
219. Hermine O, Mariette X, Tharaux PL et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia. A randomized Clinical Trial. *JAMA Intern Med* 2020.
220. Stone JH, Frigault MJ, Sterling-Boyd NJ et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. *N Engl J Med* 2020.
221. Salvarani C, Dolci G, Massari M et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. *JAMA Intern Med* 2020.
222. Bassetti M, Kollef MH, Timsit JF. Bacterial and fungal superinfections in critically ill patients with COVID-19. *Intensive Care Med* 2020.
223. Xu Q, Wang T, Quin X et al. Early awake prone position combined with high-flow nasal oxygen therapy in severe COVID-19; a case series. *Crit Care* 2020; 24:250.
224. Elharrar X, Trigui Y, Dois AM et al. Use of prone positioning in nonintubated patients with COVID-19 and hypoxemic acute respiratory failure. *JAMA* 2020.
225. Keith P, Day M, Perkins L et al. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. *Crit Care* 2020.
226. Keith P, Wells AH, Hodges J et al. The therapeutic efficacy of adjunct therapeutic plasma exchange for septic shock with multiple organ failure: A single center experience. *Crit Care* 2020; 24:518.
227. Busund R, Koukline V, Utrobin U et al. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. *Intensive Care Med* 2002; 28:1434-39.
228. Morath C, Weigand MA, Zeier M et al. Plasma exchange in critically ill COVID-19 patients. *Crit Care* 2020; 24:481.
229. Khamis F, Al-Zakwani I, Al Hashmi S et al. Therapeutic plasma exchange in adults with severe COVID-19 infection. *Int J Infect Dis* 2020.
230. Fernandez J, Gratacos-Gines J, Olivas P et al. Plasma exchange: An effective rescue therapy in critically ill patients with Coronavirus Disease 2019 infection. *Crit Care Med* 2020.
231. Gucyetmez B, Atalan HK, Sertdemir I et al. Therapeutic plasma exchange in patients with COVID-19 pneumonia in intensive care unit: a retrospective study. *Crit Care* 2020; 24:492.
232. Poor HD, Ventetuolo CE, Tolbert T et al. COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis. *medRxiv* 2020.
233. Wang J, Najizadeh N, Moore EE et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated respiratory distress syndrome (ARDS): A case series. *J Thromb Haemost* 2020.
234. Henry MB, Lippi G. Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis of early reports. *J Crit Care* 2020; 58:27-28.
235. Abrams D, Lorusso R, Vincent JL et al. ECMO during the COVID-19 pandemic: when is it unjustified. *Crit Care* 2020; 24:507.

236. Barbaro RP, MaLaren G, Boonstra PS et al. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. *Lancet* 2020.
237. Abou-Arab O, Huette P, Debouvries F et al. Inhaled nitric oxide for critically ill Covid-19 patients: a prospective study. *Crit Care* 2020; 24:645.
238. Bagate F, Tuffet S, Masi P et al. Rescue therapy with inhaled nitric oxide and almitrine in COVID-19 patients with severe acute respiratory distress syndrome. *Ann Intensive Care* 2020.
239. Caplan M, Goutay J, Bignon A et al. Almitrine infusion in severe acute respiratory syndrome coronavirus-2 induced acute respiratory distress syndrome: A single-center observational study. *Crit Care Med* 2020.
240. Payen D. Coronavirus disease 2019 acute respiratory failure: Almitrine drug resuscitaion or resuscitating patients by almitrine? *Crit Care Med* 2020.
241. Zeng QL, Yu ZJ, Gou JJ et al. Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients. *Clin Infect Dis* 2020.
242. Li L, Zhang W, Hu Y et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. A randomized clinical trial. *JAMA* 2020; 324:460-470.
243. Fleming AB, Raabe V. Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement [letter]. *J Clin Virol* 2020; 127:104388.
244. Duan K, Liu B, Li C et al. Effectiveness of convalescent plasma therapy in severe COVID-10 patients. *PNAS* 2020.
245. Cerutti A, Chen K, Chorny A. Immunoglobulin responses at the mucosal interface. *Annu Rev Immunol* 2011; 29:273-93.
246. Jacobs JJ. Neutralizing antibodies mediate virus-immue pathology of COVID-19. *Med Hypotheses* 2020; 143:109884.
247. Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Febratinib. *J Microbiol Immunol Infect* 2020.
248. Favalli EG, Biggioggero M, Maioli G et al. Baricitinib for COVID-19: a suitable treatment? *Lancet Infect Dis* 2020.
249. Mehta P, McAuley DF, Brown M et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 2020; 395:1033-34.
250. Kalil AC, Patterson TF, Mehta AK et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. *N Engl J Med* 2020.
251. Seifirad S. Pirfenidone: A novel hypothetical treatment for COVID-19. *Medical Hypotheses* 2020; 144:11005.
252. Saba A, Vaidya PJ, Chavhan VB et al. Combined pirfenidone, azithromycin and prednisolone in post-H1N1 ARDS pulmonary fibrosis. *Sarcoidosis Vasc Diffuse Lung Dis* 2018; 35:85-90.
253. Spagnolo P, Balestro E, Aliberti S et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? *Lancet Resp Med* 2020; 8:750-752.
254. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antibibrotic therapy. *Lancet Resp Med* 2020; 8:807-15.
255. Brouwer WP, Duran S, Kuijper M et al. Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study. *Crit Care* 2019; 23:317.
256. Villa G, Romagnoli S, De Rosa S et al. Blood purification therapy with a hemodiafilter featuring enhanced adsorptive properties for cytokine removal in patients presenting COVID-19: a pilot study. *Crit Care* 2020; 24:605.
257. Bryce C, Grimes Z, Pujadas E et al. Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. *The Mount Sinai COVID-19 autopsy experience*. medRxiv 2020.
258. Slaats J, ten Oever J, van de Veerdonk FL et al. IL-1B/IL-6/CRP and IL-18/ferritin: Distinct inflammatory programs in infections. *PLoS Pathog* 2016; 12:e1005973.
259. Colafrancesco S, Alessandri C, Conti F et al. COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome? *Autoimmunity Reviews* 2020; 19:102573.
260. Giamarellos-Bouboulis EJ, Netea MG, Rovina N et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. *Cell Host & Microbe* 2020.
261. McGonagle D, Sharif K. The role of cytokines including interleukin-6 in COVID-19 induces pneumonia and macrophage activation syndrome-like disease. *Autoimmunity Reviews* 2020.

262. Kyriazopoulou E, Leventogiannis K, Norrby-Teglund A et al. Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. *BMC Medicine* 2017; 15:172.
263. Tan C, Huang Y, Shi F et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. *J Med Virol* 2020; 92:856-62.
264. Howell AP, Parrett JL, Malcom DR. Impact of high-dose intravenous vitamin C for treatment of sepsis on point-of-care blood glucose readings. *J Diabetes Sci Technol* 2019.
265. Stephenson E, Hooper MH, Marik PE. Vitamin C and Point of Care glucose measurements: A retrospective, Observational study [Abstract]. *Chest* 2018; 154 (suppl.):255a.
266. Brosnahan SB, Bhatt A, Berger JS et al. COVID-19 pneumonia hospitalizations followed by re-presentation for presumed thrombotic event. *Chest* 2020.
267. Spyropoulos AC, Lipardi C, Xu J et al. Modified IMPROVE VTE Risk Score and elevated D-Dimer identify a high venous thromboembolism risk in acutely ill medical population for extended thromboprophylaxis. *TH Open* 2020; 4:e59-e65.
268. Kunutsor SK, Seidu S, Blom AW et al. Serum C-reactive protein increases the risk of venous thromboembolism: a prospective study and meta-analysis of published prospective evidence. *Eur J Epidemiol* 2017; 32:657-67.
269. Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. *JAMA* 2020.
270. Prescott HC, Girard TD. Recovery from Severe COVID-19. Leveraging the lessons of survival from sepsis. *JAMA* 2020.
271. Greenhalgh T, Knight M, A'Court C et al. Management of post-acute Covid-19 in primary care. *BMJ* 2020.
272. Chopra V, Flanders SA, O'Malley M. Sixty-day outcomes among patients hospitalized with COVID-19. *Ann Intern Med* 2020.
273. Mandal S, Barnett J, Brill SE et al. 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalization for COVID-19. *Thorax* 2020.
274. Michelen M, Manoharan L, Elkheir N et al. Characterising long-term covid-19: a rapid living systematic review. *medRxiv* 2020.
275. Lu Y, Li X, Geng D et al. Cerebral micro-structural changes in COVID-19 patients - An MRI-based 3-month follow-up study. *EclinicalMedicine* 2020.
276. Riche F. Protracted immune disorders at one year after ICU discharge in patients with septic shock. *Crit Care* 2018; 22:42.
277. Andreacos E, Papadaki M, Serhan CN. Dexamethasone, pro-resolving lipid mediators and resolution of inflammation in COVID-19. *Allergy* 2020.
278. Dalli J, Chiang N, Serhan CN. Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections. *Nat Med* 2015; 21:1071-75.
279. Aguirre-Chang G, Castillo Saavedra E, Yui Cerna M et al. Post-acute or prolonged COVID-19: Treatment with ivermectin for patients with persistent, or post-acute symptoms. *Research Square* 2020.
280. Gao J, Zheng P, Jia Y et al. Mental health problems and social media exposure during COVID-19 outbreak. *PLoS ONE* 2020; 15:e0231924.
281. Pennycook G, McPhetres J, Zhang Y et al. Fighting COVID-19 misinformation on Social Media: Experimental Evidence for a Scalable Accuracy-Nudge Intervention. *Psychological Science* 2020; 31:770-780.
282. Kurcicka L, Lauer SA, Laeyendecker O et al. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. *Ann Intern Med* 2020; 173:262-67.
283. Cheng HY, Jian SW, Liu DP et al. Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset. *JAMA Intern Med* 2020; 180:1156-63.
284. Zhao J, Yang Y, Huang H et al. Relationship between ABO blood group and the COVID-19 susceptibility. *medRxiv* 2020.
285. Banerjee A, Pasea L, Harris S et al. Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. *Lancet* 2020; 395:1715-25.
286. Goren A, Vamo-Galvan S, Wambier CG et al. A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain- A potential clue to the role of androgens in COVID-19 severity. *J Cosmetic Dermatol* 2020.

287. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; 395:497-506.
288. Guan W, Ni Z, Hu Y et al. Clinical characteristics of Coronavirus disease 2019 in China. *N Engl J Med* 2020.
289. von der Thusen J, van der Eerden M. Histopathology and genetic susceptibility in COVID-19 pneumonia. *Eur J Clin Invest* 2020.
290. Sweeney TE, Liesenfeld O, Wacker J et al. Validation of inflammopathic, adaptive, and coagulopathic sepsis endotypes in Coronavirus disease 2019. *Crit Care Med* 2020.
291. Tartof SY, Qian L, Hong V et al. Obesity and mortality among patients diagnosed with COVID-19: Results from an integrated health care organization. *Ann Intern Med* 2020.
292. Pujadas E, Chaudhry F, McBride R et al. SARS-CoV-2 viral load predicts COVID-19 mortality. *Lancet Resp Med* 2020.
293. Akbar AN, Gilroy DW. Aging immunity may exacerbate COVID-19. *Science* 2020; 369.
294. Zhang Q, Bastard P, Liu Z et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science* 2020.
295. Zhou Y, Fu B, Zheng X et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. *Natl Sci Rev* 2020; 7:998-1002.
296. Blanco-Melo D, Nilsson-Payant BE, Liu WC et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. *Cell* 2020.
297. Zhou F, Yu T, Du R et al. Clinical course and risk factor for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020.
298. Giamarellos-Bourboulis EJ, Netea MG, Rovina N et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. *medRxiv* 2020.
299. Qin C, Zhou L, Hu Z et al. Dysregulation of the immune response in patients with COVID-19 in Wuhan, China. *Lancet Infect Dis* 2020.
300. Zhang C, Wu Z, Li JW et al. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonists Tocilizumab may be the key to reduce the mortality. *Int J Antimicrob Agents* 2020.
301. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the "Cytokine Storm" in COVID-19. *J Infection* 2020.
302. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. *Science* 2020.
303. Tay MZ, Poh CM, Renia L et al. The trinity of COVID-19: immunity, inflammation and intervention. *Nature Reviews* 2020; 20:363-74.
304. Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. *Intensive Care Med* 2020; 46:1105-8.
305. Teuwen LA, Geldhof V, Pasut A et al. COVID-19: the vasculature unleashed. *Nature Reviews* 2020.
306. Varga Z, Flammer AJ, Steiger P et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet* 2020.
307. Ackermann M, Verleden SE, Kuehnel M et al. Pulmonary vascular endothelialitis, Thrombosis, and Angiogenesis in COVID-19. *N Engl J Med* 2020; 383:120-128.
308. Kory P, Kanne JP. SARS-CoV-2 organizing pneumonia: "Has there been a widespread failure to identify and treat this prevalent condition in COVID-19?". *BMJ Open Resp Res* 2020; 7:e000724.
309. Torrealba JR, Fisher S, Kanne JP et al. Pathology-radiology correlation of common and uncommon computed tomographic patterns of organizing pneumonia. *Human Pathology* 2018; 71:30-40.
310. Kanne JP, Little BP, Chung JH et al. Essentials for radiologists on COVID-19: an Update-Radiology Scientific Expert Panel. *Radiology* 2020.
311. Copin MC, Parmentier E, Duburcq T et al. Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection [letter]. *Intensive Care Med* 2020.
312. Gattinoni L, Chiumello D, Caironi P et al. COVID-19 pneumonia: different respiratory treatment for different phenotypes? *Intensive Care Med* 2020; 46:1099-102.
313. Chiumello D, Cressoni M, Gattinoni L. Covid-19 does not lead to a "typical" Acute Respiratory Distress syndrome. *Lancet* 2020.
314. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? *Crit Care* 2020; 24:154.
315. Gattinoni L, Pesenti A. The concept of "baby lung". *Intensive Care Med* 2005; 31:776-84.
316. Jeronimo CM, Farias ME, Almeida FF et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (MetCovid): A randomised, double-blind, phase IIb, placebo-controlled trial. *Clin Infect Dis* 2020.

317. Carsana L, Sonzogni A, Nasr A et al. Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy. medRxiv 2020.
318. Menter T, Haslbauer JD, Nienhold R et al. Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. medRxiv 2020.
319. Xu Z, Shi L, Wang Y et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Resp Med 2020.
320. Tobin MJ, Laghi F, Jubran A. Why COVID-19 silent hypoxemia is baffling to physicians. Am J Respir Crit Care Med 2020.
321. Schurink B, Roos E, Radonic T et al. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe 2020.
322. Buijssers B, Yanginlar C, Maciej-Hulme ML et al. Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients. EBioMedicine 2020.
323. Kim SY, Jin W, Sood A et al. Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. Antiviral Res 2020; 181:104873.
324. Clausen TM, Sandoval DR, Spliid CB et al. SARS-CoV-2 infection depends on cellular heparan sulphate and ACE2. bioRxiv 2020.
325. Huang X, Han S, Liu x et al. Both UFH and NAH alleviate shedding of endothelial glycocalyx and coagulopathy in LPS-induced sepsis. Exp Thera Med 2020; 19:913-22.
326. Buijssers B, Yanginlar C, de Nooijer A et al. Increased plasma heparanase activity in COVID-19 patients. medRxiv 2020.
327. May JM, Qu ZC. Ascorbic acid prevents oxidant-induced increases in endothelial permeability. Biofactors 2011; 37:46-50.
328. Utoguchi N, Ikeda K, Saeki K et al. Ascorbic acid stimulates barrier function of cultured endothelial cell monolayer. Journal of Cellular Physiology 1995; 163:393-99.
329. Han M, Pendem S, Teh SL et al. Ascorbate protects endothelial barrier function during septic insult: Role of protein phosphatase type 2A. Free Radic Biol Med 2010; 48:128-35.
330. Elenkov IJ. Glucocorticoids and the Th1/Th2 balance. Ann N Y Acad Sci 2004; 1024:138-46.
331. Shodell M, Siegal FP. Corticosteroids depress INF-alpha-producing plasmacytoid dendritic cells in human blood. J Allergy Clin Immunol 2001; 108:446-48.
332. Thomas BJ, Porritt RA, Hertzog PJ et al. Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon. Scientific Reports 2014; 4:7176.
333. Singanayagam A, Glanville N, Girkin JL et al. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. Nature Communications 2018; 9:2229.
334. Salton F, Confalonieri P, Santus P et al. Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia. medRxiv 2020.
335. Braude AC, Rebuck AS. Prednisone and methylprednisolone disposition in the lung. Lancet 1983;995-97.
336. Draghici S, Nguyen TM, Sonna LA et al. COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases. Nature Reviews 2020.
337. Chen L, Li J, Luo C et al. Binding interaction of quercetin-3-B-galactoside and its synthetic derivatives with SARS-CoV 3CLpro: Structure-activity relationship studies reveals salient pharmacophore features. Bioorganic & Medicinal Chemistry 2020; 14:8295-306.
338. Ono K, Nakane H. Mechanisms of inhibition of various cellular DNA and RNA polymerases by several flavonoids. J Biochem 1990; 108:609-13.
339. Kaul TN, Middleton E, Pgra PL. Antiviral effects of flavonoids on human viruses. J Med Virol 1985; 15:71-79.
340. Shinozka K, Kikuchi Y, Nishino C et al. Inhibitory effect of flavonoids on DNA-dependent DNA and RNA polymerases. Experientia 1988; 44:882-85.
341. Martin JH, Crotty S, Warren P. Does an apple a day keep the doctor away because a phytoestrogen a day keeps the virus at bay? A review of the anti-viral properties of phytoestrogens. Phytochemistry 2007; 68:266-74.
342. Smith M, Smith JC. Repurposing therapeutics for COVID-19: Supercomputer-based docking to the SARS-CoV-2 viral spike protein and viral spike protein-human ACE2 interface. ChemRxiv 2020.
343. Leyva-Lopez N, Gutierrez-Grijalva EP, Ambriz-Perez D. Flavonoids as cytokine modulators: A possible therapy for inflammation-related diseases. Int J Mol Sci 2016; 17:921.

344. Nair MP, Kandaswami C, Mahajan S et al. The flavonoid, quercetin, differentially regulates Th-1 (INF) and Th-2 (IL4) cytokine gene expression by normal peripheral blood mononuclear cells. *Biochimica et Biophysica Acta* 2020; 1593:29-36.
345. Dabbagh-Bazarbachi H, Clergeaud G, Quesada IM et al. Zinc ionophore activity of Quercetin and Epigallocatechin-gallate: From Hepa 1-6 cells to a liposome model. *J Agric Food Chem* 2014; 62:8085-93.
346. Rhodes J, Dunstan F, Laird E et al. COVID-19 mortality increases with northerly latitude after adjustment for age suggesting a link with ultraviolet and vitamin D. *BMJ Nutrition, Prevention & Health* 2020.
347. Tang N, Bai H, Chen X et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 with coagulopathy. *medRxiv* 2020.
348. Sardu C, Gambardella J, Morelli MB et al. Is COVID-19 an endothelial disease? Clinical and basic evidence. *medRxiv* 2020.
349. World Health Organization: Coronavirus Disease 2019 (COVID-19): Situation Report -54 (14th March 2020). <https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200314-sitrep-54-covid-19.pdf> . 2020. 7-9-2020.
350. Clinical management of COVID-19. Interim guidance. 27th May 2020. <https://www.who.int/publications/i/item/clinical-management-of-covid-19> WHO/2019-nCoV/clinical/2020.5 . 2020. World Health Organization. 7-10-2020.
351. Yam LY, Lau AC, Lai FY et al. Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. *J Infection* 2007; 54:28-39.
352. Siemieniuk RA, Bortoszko JJ, Ge L et al. Drug treatments for Covid-19: living systematic review and network meta-analysis. *BMJ* 2020.
353. Saune PM, Bryce-Alberti M, Portmann-Baracco AS et al. Methylprednisolone pulse therapy: An alternative management of severe COVID-19. *Respiratory Medicine Case Reports* 2020; 31:101221.
354. Fernandez-Cruz A, Ruiz-Antoran B, Gomez AM et al. Impact of glucocorticoid treatment in SARS-CoV-2 infection mortality: A retrospective controlled cohort study. *medRxiv* 2020.
355. Corral-Gudino L, Bahamonde A, Arnaiz-Revillas F et al. GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. *medRxiv* 2020.
356. Stauffer WM, Alpern JD, Walker PF. COVID-19 and dexamethasone. A potential strategy to avoid steroid-related Strongyloides hyperinfection. *JAMA* 2020; 324:623-24.